

# Gut Microbiota in Therapeutic Approaches for Alcoholic Liver Disease

Lead Guest Editor: Laura Nagy

Guest Editors: Michele T. Pritchard, Sanjoy Roychowdhury, Gaurisankar Sa, and Colleen Croniger





---

# **Gut Microbiota in Therapeutic Approaches for Alcoholic Liver Disease**

Mediators of Inflammation

---

## **Gut Microbiota in Therapeutic Approaches for Alcoholic Liver Disease**

Lead Guest Editor: Laura Nagy

Guest Editors: Michele T. Pritchard, Sanjoy  
Roychowdhury, Gaurisankar Sa, and Colleen  
Croniger




Copyright © 2022 Hindawi Limited. All rights reserved.





This is a special issue published in “Mediators of Inflammation.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



# Chief Editor























Anshu Agrawal , USA

## Associate Editors

Carlo Cervellati , Italy  
Elaine Hatanaka , Brazil  
Vladimir A. Kostyuk , Belarus  
Carla Pagliari , Brazil

## Academic Editors




Amedeo Amedei , Italy  
Emiliano Antiga , Italy  
Tomasz Brzozowski , Poland  
Daniela Caccamo , Italy  
Luca Cantarini , Italy  
Raffaele Capasso , Italy  
Calogero Caruso , Italy  
Robson Coutinho-Silva , Brazil  
Jose Crispin , Mexico  
Fulvio D'Acquisto , United Kingdom  
Eduardo Dalmarco , Brazil  
Agnieszka Dobrzyn, Poland  
Ulrich Eisel , The Netherlands  
Mirvat El-Sibai , Lebanon  
Giacomo Emmi , Italy  
Claudia Fabiani , Italy  
Fabiola B Filippin Monteiro , Brazil  
Antonella Fioravanti , Italy  
Tânia Silvia Fröde , Brazil  
Julio Galvez , Spain  
Mirella Giovarelli , Italy  
Denis Girard, Canada  
Markus H. Gräler , Germany  
Oreste Gualillo , Spain  
Qingdong Guan , Canada  
Tommaso Iannitti , United Kingdom  
Byeong-Churl Jang, Republic of Korea  
Yasumasa Kato , Japan  
Cheorl-Ho Kim , Republic of Korea  
Alex Kleinjan , The Netherlands  
Martha Lappas , Australia  
Ariadne Malamitsi-Puchner , Greece  
Palash Mandal, India  
Joilson O. Martins , Brazil  
Donna-Marie McCafferty, Canada  
Barbro N. Melgert , The Netherlands

Paola Migliorini , Italy  
Vinod K. Mishra , USA  
Eeva Moilanen , Finland  
Elena Niccolai , Italy  
Nadra Nilsen , Norway  
Sandra Helena Penha Oliveira , Brazil  
Michal A. Rahat , Israel  
Zoltan Rakonczay Jr. , Hungary  
Marcella Reale , Italy  
Emanuela Roscetto, Italy  
Domenico Sergi , Italy  
Mohammad Shadab , USA  
Elena Silvestri, Italy  
Carla Sipert , Brazil  
Helen C. Steel , South Africa  
Saravanan Subramanian, USA  
Veendamali S. Subramanian , USA  
Taina Tervahartiala, Finland  
Alessandro Trentini , Italy  
Kathy Triantafilou, United Kingdom  
Fumio Tsuji , Japan  
Maria Letizia Urban, Italy  
Giuseppe Valacchi , Italy  
Kerstin Wolk , Germany  
Soh Yamazaki , Japan  
Young-Su Yi , Republic of Korea  
Shin-ichi Yokota , Japan  
Francesca Zimetti , Italy

## Contents


---

### **Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease**

Dhara Patel , Dixa Sharma , and Palash Mandal 

Review Article (11 pages), Article ID 4230599, Volume 2022 (2022)

### **Prophylactic Treatment of Probiotic and Metformin Mitigates Ethanol-Induced Intestinal Barrier Injury: *In Vitro*, *In Vivo*, and *In Silico* Approaches**

Farhin Patel , Kirti Parwani , Priyashi Rao , Dhara Patel , Rakesh Rawal , and Palash Mandal 

Research Article (32 pages), Article ID 5245197, Volume 2021 (2021)

## Review Article

# Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease

Dhara Patel , Dixa Sharma , and Palash Mandal 

*PD Patel Institute of Science and Technology, Charotar University of Science and Technology, 388421, Changa, Gujarat, India*

Correspondence should be addressed to Palash Mandal; [palashmandal.bio@charusat.ac.in](mailto:palashmandal.bio@charusat.ac.in)

Received 20 September 2021; Revised 19 January 2022; Accepted 20 April 2022; Published 20 May 2022

Academic Editor: Michele T. Pritchard

Copyright © 2022 Dhara Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Consumption of alcohol (ethanol) in various forms has been an integral part of human civilization. Since ages, it also has been an important cause of death and health impairment across the globe. Ethanol-mediated liver injury, known as alcoholic liver disease (ALD), is caused by surplus intake of alcohol. Several studies have proposed the different pathways that may lead to ALD. One of the factors that may affect the cytochrome P450 (CYP2E1) metabolic pathway is gut dysbiosis. The gut microbiota produces various compounds that play an important role in regulating healthy functions of distal organs such as the adipose tissue and liver. Dysbiosis causes bacteremia, hepatic encephalopathy, and increased intestinal permeability. Recent clinical studies have found better understanding of the gut and liver axis. Another factor that may affect the ALD pathway is dysfunction of adipose tissue metabolism. Moreover, dysfunction of adipose tissue leads to ectopic fat deposition within the liver and disturbs lipid metabolism by increasing lipolysis/decreasing lipogenesis and impaired glucose tolerance of adipose tissue which leads to ectopic fat deposition within the liver. Adipokine secretion of resistin, leptin, and adiponectin is adversely modified upon prolonged alcohol consumption. In the combination of these two factors, a proinflammatory state is developed within the patient leading to the progression of ALD. Thus, the therapeutic approach for treatments and prevention for liver cirrhosis patients must be focused on the gut-liver-adipose tissue network modification with the use of probiotics, synbiotics, and prebiotics. This review is aimed at the effect of ethanol on gut and adipose tissue in both rodent and human alcoholic models.

## 1. Introduction

In 2018, according to World Health Organization (WHO) global report on alcohol and health, nearly 3 million people died in the year 2016 due to abuse of alcohol [1]. Alcohol consumption has been found to be one of the major causes of organ dysfunction and tissue injury leading to the ALD, cancer, compromised immune system, pancreatitis, heart diseases, and disturbance in circadian clock [2]. Although alcohol is primarily necessary for organ dysfunction, it is not the only factor causing ALD. Subsequently, other factors that contribute to the toxicity of alcohol pathology are the alcohol-induced modifications in the composition and function of the gastrointestinal tract (GIT) microbiota and function of adipose tissue.

The GIT contains trillions of microbes with more than 1000 different species; the major groups from the vast phyla are *Firmicutes* and *Bacteroidetes* [3]. There is a symbiotic

relationship between the microbes of the intestine and GIT. Gut microbiota helps in the extraction of energy and synthesis of amino acids and vitamins from food as well as maintaining the vital barriers against pathogens and therefore maintaining the general homeostasis of a healthy human being. With disturbance in the healthy microbiome of GIT, the homeostasis might also be affected and prolonged alteration may cause ALD, inflammatory bowel disease (IBD), type I and II diabetes, and cardiovascular disease [2]. However, it is not yet evident whether dysbiosis is the cause of the disease or the outcome of disease.

Chronic alcohol consumption leads to lipolysis and ectopic fat deposition in the liver which signifies the importance of function of adipose tissue in progression of ALD [3]. Function of adipose tissue derived fatty acids and lipid metabolism is impaired due to chronic alcoholism. Moreover, in long-term exposure to alcohol, lipogenesis is decreased and lipolysis is increased leading to fat loss [4, 5].

White adipose tissue (WAT) is an endocrine organ which releases several adipokines such as adiponectin, leptin, and resistin which are modulated negatively in ALD [6, 7]. Tumor necrosis factor alpha (TNF- $\alpha$ ), Interleukin-6 (IL-6), and Monocyte chemoattractant protein-1 (MCP-1) are essential modulators of lipid metabolism and are affected by chronic alcoholism [8]. Lastly, a proinflammatory state developed within WAT contributes to lipodystrophy resulting in fat deposition in the peripheral organs, which enhances the pathological state of ALD. Therefore, this review focuses on the current knowledge of regulation of gut microbiota composition and adipose tissue in ALD.

## 2. Gut Microbiota Composition Analyses with Intake of Alcohol

Due to the vast genetic diversity, it is incredibly difficult for absolute characterization of microbial communities in the GIT. Thus, researchers use molecular tools such as RNA, DNA, and PCR-based target approaches from colonic tissue biopsies and fecal samples to analyze these complex GIT communities. A supporting study of four healthy individuals on microbiota community in the stomach, mouth, duodenum, colon, and stool showed that the context of GIT and feces is mostly similar. However, three of four individuals had reduced number of *Bacteroidetes* in fecal samples, resulting in the alteration of the *Firmicutes* and *Bacteroidetes* ratio, which is used as a diagnostic parameter for ALD [9].

An inadequate study has been performed on correlating the structure and activity of GIT microbiota under the influence of alcohol as compared to other effects on the body. Previous studies suggest that C57BL/6 mice that were fed 30.9 g/kg per day of alcohol for 3 weeks have developed ALD as compared to the control group. The study observed the bacterial overgrowth in a small intestine and cecum dysbiosis [10]. In another rat model study, 10-week alcohol feeding (8 g/kg/day) experiment found the occurrence in dysbiosis with alcohol induced endotoxemia [11]. These studies evidently suggested that alteration of microbiota, intestinal permeability, proinflammatory factors, and endotoxemia may potentially contribute to liver pathology or intestinal dysbiosis [12].

Supporting evidences were also found in humans. A study of shotgun metagenomic sequencing elucidated that the sensitive microbial pathways are altered consistently with the degree of hepatic steatosis in the patients who have stop drinking alcohol for 2 weeks [13]. A study reported that minimal hepatic encephalopathy (MHE) and liver cirrhosis have found overgrowth of aerobic and anaerobic bacteria in the small intestine using a culture-based method [14]. Another study of sigmoid biopsies from alcoholic and healthy individuals showed alteration of mucosa associated microbiota [15]. An *in vivo* study also suggests the detection of higher level of endotoxin and bacterial products in the blood circulation, signifying the hyperpermeability of the intestinal lumen [16]. Evidential increase in the families of *Prevotellaceae*, *Enterobacteriaceae*, *Veillonellaceae*, and *Streptococcaceae* was observed in the alcoholic cirrhosis patients as compared to the hepatitis B control group [17].

Another interesting study suggests the microbial community difference in the alcoholics and alcoholic cirrhotic patients. Apparently, alcoholic without cirrhosis patients have shown decrease in *Veillonellaceae* and *Clostridia* spp. while alcoholic with cirrhosis patients have shown an increase in *Veillonellaceae*, *Prevotellaceae*, *Enterobacteriaceae*, and *Fusobacteria* which may affect the prognosis of the patient condition [18]. These differences in finding of bacterial community between alcoholics and alcoholic cirrhosis may result in the progression of the liver disease or may act as a biomarker for the same. More studies are required to determine the relationship between the microbiota and liver diseases under the influence of chronic alcohol.

Alcohol consumed in certain amount can be beneficial for GIT microbial composition. One such study was performed where red wine (272 mL per day), dealcoholized red wine (272 mL per day), or gin (100 mL per day) for 20 days was consumed by the patients. Red wine and dealcoholized red wine consumption increased the abundance of beneficial bacteria *Bifidobacterium* in the GIT. Consumption of gin increases *Clostridium* when compared to dealcoholized red wine drinking which increases *Fusobacteria* [19]. It has been evident that consumption of polyphenols is linked with growth in bacteria which are known to promote healthy ecosystem of GIT. Thus, they can be utilized as dietary supplements to alter the bacterial community in a specific way. Additionally, regular intake of red wine polyphenols rises the growth of *Bifidobacterium* which could be allied as a prebiotic effect on gut microbiota [20]. A study on alcoholic hepatitis patients has shown negative correlation between liver disease score and Shannon diversity; further relative abundance of *Akkermansia* is decreased, and that of *Veillonella* is increased. Also, antibiotic-treated patients have shown reduction in *Bacteroides* and Shannon diversity, while patients on steroids have increase in *Veillonella* abundance. It was signified that the modification in the gut microbiome in alcoholic hepatitis patient is distinct and can be an attractive target for prevention or treat ALD [21]. Alcohol altering the gut microbiota or the disturbance in gut microbiota leading to progression of ALD is yet to be completely understood and recognized.

## 3. Overview of the Dysbiosis Linkage in ALD Progression

The pathological onsets during chronic consumption of alcohol are gradual, with the change in the gut microbiota under the persistent influence of alcohol [20]. Studies have shown that the oxidative stress in the intestinal lumen caused by alcohol consumption disrupts the tight junction of the intestine leading to intestinal hyperpermeability [20], due to which the translocation of gram-negative bacteria and its products occur through portal vein circulation. Exposure to such endotoxins can cause inflammation in the liver, which would add to the conjunction effect of direct alcohol and cause ALD. Overgrowth of bacteria or translocation of the bacterial products or metabolites may cause infection and may result in mortality of the ALD cirrhotic patients [22]. It has also been reported that leaky gut alone did not

explain increased microbial translocation in patients. Rather, duodenal dysbiosis with an increase in *Streptococcus*, *Shuttleworthia*, and *Rothia* leads to intestinal permeability and elevated markers of microbial translocation in alcoholic disorder patients with progressive ALD [23]. A study on peroxisome proliferator-activated receptors- $\delta$  (PPAR  $\delta$ ) suggests that activation of PPAR  $\delta$  agonist seladelpar elevates proliferation of epithelial cells in the small intestine and suppresses macrophage-derived inflammation as a result of stabilizing gut barrier function and dysbiosis [24]. Gut signifies a vital role in the prognosis of ALD and therapeutic approaches.

#### 4. *Lactobacillus* Used to Modify Gut Microbiota in Alcoholic Liver Disease

Probiotic and synbiotic intervention may modify the dysbiosis caused by ALD. Probiotics are defined as live organisms that are beneficial to host more than their nutrition value [25], while synbiotics are combinations of prebiotic (nondigestible fibers) and probiotic that stimulate growth of microbiota in the intestine. *Lactobacillus rhamnosus* GG (LGG) is one of the most studied probiotic bacterial strains which is known to be effective for intestinal development and immunity, ameliorate diarrhea, ulceration, colitis, and improved intestinal barrier function [26, 27].

A study suggested that with the administration of LGG ( $2.5 \times 10^7$  cfu/mL), oats (10 g/kg) along with alcohol (8 gm/kg/day) for 10 weeks in SD rats resulted in the prevention of alcohol associated dysbiosis [9]. Amelioration of intestinal hyperpermeability and oxidative stress are few of the factors that altered the progression of alcohol steatohepatitis [28]. Another study also supports the beneficial role of LGG, where 1 mL of LGG along with Lieber-DeCarli Diet, with and without 5% (w/v) alcohol, was found to decrease the count of *Bacteroidetes* but *Firmicutes*, *Proteobacteria*, and *Actinobacteria* increased considerably [29]. However, LGG administration did increase the *Firmicutes* along with *Lactobacillus*, while other studies have suggested the prevention of ALD by maintaining the gut permeability, endotoxemia, and liver injury [30, 31]. Human studies with LGG administration show that minimal hepatic encephalopathy (MHE) patients with cirrhosis do have beneficial microbial growth but do not have increased *Lactobacillus* or improved cognitive function [14]. The above-mentioned studies can confirm that use of probiotic or synbiotics can alter the host microbiota in a more beneficial way for the clinical trial. With the gut dysbiosis, the second hit of alcohol consumption is on the adipose tissue in ALD.

#### 5. Adipose Tissue Metabolism in the Presence of Alcohol

The progression of ALD is a multifactorial disease condition. The above-mentioned facts indicate that prevention is better than cure as the life expectancy of the patients after clinical diagnosis of alcoholic steatohepatitis (ASH) is very short [32, 33]. The known deleterious consequences of alcohol from hepatic oxidative stress, inflammation, and cell apopto-

sis may not be the only route for the progression of ALD. Adipose tissue is mainly considered the primary organ for storage, but the recent advancement has discovered that adipokines have led to considering the white adipose tissue (WAT) as a major endocrine organ [34–36]. Thus, dysfunction of adipose tissue might be correlated with the pathophysiology of many metabolic diseases including alcoholic liver disease as shown in Figure 1 [37].

Dysfunction of adipose tissue may affect the hepatic metabolism by adipocyte cell death and inflammation release of free fatty acids (FFA) [8]. Simultaneously, release of endotoxin from the compromised gut microbiota in portal circulation may play an important role in mediating inflammatory responses and liver injury in the presence of alcohol [38–42]. Thus, the dual hit of inflammation in adipose tissue and leaky gut plays a vital role in the progression of ALD.

The process of production of FFA and glycerol from the hydrolysis of triglyceride as an energy source by other tissues during inflammation is known as lipolysis [43]. These circulating FFA are normally removed by the liver. An *in vivo* radio-labeled triglyceride study suggested the increase of lipolysis in adipose tissue upon intake of chronic ethanol [37, 44]. Catecholamine like epinephrine and norepinephrine stimulation via B adrenergic receptor is a potential activator for lipolysis upon intake of alcohol [45]. Lipolysis is also activated by fibroblast growth factor 21 (FGF21) to reduce accumulation of lipid via peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) and CCAT-enhancer-binding protein (C/EBP). WAT is mainly responsible for the secretion of FGF21 as energy responsive adipokines in the presence of glucose metabolism in the adipose tissue [44].

To support the role of FGF21, a deficiency of FGF21 upon intake of chronic-binge alcohol resulted in the increase of plasma and eWAT FGF21 expression, and increase in lipolysis was prevented [45]. A contradicting study in FGF21 knockout mice indicated the decrease in plasma catecholamine concentration and eWAT mass [43]. The role of FGF21 as a metabolic regulator upon alcohol intoxication requires further investigation. In contrast to lipolysis, the process of energy storage is known as lipogenesis, while effects of alcohol on lipolytic surpass its lipogenic effects.

Alcohol does alter the lipogenic pathway. After chronic ethanol consumption, PPAR $\gamma$  decreased in WAT, which is known as a prominent lipogenic stimulant [46–48]. The mitogen-activated protein kinase (MAPK) pathway regulates PPAR $\gamma$ . Thus, the partial suppression of MAPK helps to restore levels of PPAR $\gamma$  [49]. The effect of chronic alcohol intake on modulators of lipid metabolism relies on the *in vivo* vs. *in vitro* model system. Finally, *in vivo* administration of labeled triglyceride into chronic ethanol fed rats did not indicate any significant difference in the synthesis of triglyceride [37], since early changes developed by alcohol intake give insight into the initiation of long-term effects induced by lipodystrophy.

Adipose tissue also contains visceral adipose tissue (VAT) which is also affected upon intake of alcohol. In one of the studies, the possible mechanism upon alcohol






FIGURE 1: Effect of ethanol on adipose tissue contributing to the advancement of alcoholic liver disease condition.

induction suggested that increase in VAT and hypertrophic adipocytes leads to hypoxia which induces factor-1A (HIF-1A) and GLUT1 activation resulting in inflammation of the adipocytes and secretion of inflammatory adipokines such as leptin, TNF- $\alpha$ , and IL-6, which are vital for the prognosis of ALD [50, 51].

Binge or chronic alcohol consumption affects the body as a whole. The immunomodulatory response to the alcohol affects antimicrobial defense and inflammatory responses which results in the prognosis of the disease. Immunometabolism between adipose tissue and systemic metabolism plays a significant role in impairing the insulin uptake [49]. Mechanisms of homeostasis of immune cell-mediated metabolic responses in adipose tissue in ALD are not known. Another study in the rat model suggested mesenteric lymphatic leak, presence of dendritic cells and  $T_{reg}$  into perilymphatic adipose tissue, decreased CD4/CD8 ratio in the mesenteric lymph node, and decreased glucose uptake by perilymphatic adipose tissue indicating possible dysregulation of immunometabolism [52].

It is well established that ethanol consumption increases reactive oxygen species (ROS) in a central mechanism, which induces vascular toxicity [53–55]. Acute ethanol consumption is also linked with cardiovascular events [56]. The enzyme NADPH oxidase produces ROS in both vascular and endothelial muscle cells [57]. In the vasculature, acute ethanol intake activates NAD(P)H oxidase which further leads to elevation of  $O_2^-$  and lipoperoxidation [55, 58].

Vascular composition such as perivascular adipose tissue (PVAT) is a vital modulator of various agonists in vascular contraction of blood vessels [59, 60]. Thus, PVAT functions

as a paracrine modulator for secreting adipocyte-derived relaxing factors (ADRF), which are still not completely characterized [61]. PVAT regulates vasoconstriction through ADRF and can also contract perivascular nerve stimulation as it comprises reactive oxygen species and superoxide anion [62]. In a study of acute ethanol exposure in rats, the observation suggested that PVAT protects against vascular dysfunction through increased production of  $H_2O_2$  [56]. This can be a possible new mechanism of deposition of VAT resulting in hypoxia and inflammation within the tissue.

The specific immune response that drives the dysfunction of adipose tissue is not known. Another possible mechanism is the role of toll-like receptor 4 (TLR4) in adipocyte metabolism. Due to deposition of lipids in hepatocytes, the adipose tissue is the second organ being affected in pathogenesis of ALD. Several chronic alcoholic studies reported that PPAR $\gamma$ , CYP2E1, Bid, and C1q are potential mediators for the inflammation in adipose tissue [63–65]. Simultaneously, anti-inflammatory adipokines are decreased in adipose tissue [66]. This phenomenon will trigger the inflammatory state in adipose tissue resulting in metabolic dysfunction of both the adipose tissue and liver [49]. A previous study suggests that in the absence of TLR 4 knocked out, TLR 2 and 9 are involved in the inflammation in adipose tissue [49, 67]. TLR4 expression in a nonmyeloid cell type can switch M1 macrophage phenotype. While in myeloid cells, dendritic cell accumulation is absent when TLR4 is deleted in the presence of alcohol. Accumulation of neutrophil and depletion of CD8 $^+$  T-cell are not dependent on TLR4. These conclusions help determine a role of adipose tissue inflammation in ALD [68].

## 6. Role of CYP2E1 in Adipose Tissue and Innate Immunity in ALD

Ethanol is metabolized by CYP2E1 leading to oxidative and endoplasmic stress, which alters adipokine regulation leading to prognosis of ALD. 4-Hydroxynonenal, an indicator of oxidative stress, was identified in the adipose tissue upon chronic ethanol feeding [44, 69]. Progression of inflammation in adipose tissue is co-related with the increase of ethanol induced CYP2E1 expression via triggering redox-sensitive transcription factors that leads to increase in ROS production. Moreover, amplified CYP2E1 expression also leads to activation of C1q-dependent complement system and apoptosis facilitated by Bid causing a secondary CYP2E1 facilitated inflammatory response [70]. Simultaneously, levels of macrophage migration inhibitory factor (MIF) and inflammatory cytokines are amplified in alcoholic cirrhosis patients, though the exact mechanism of MIF increase is unknown [71–73]. Disruption of adipokine release from adipose tissue and increase in filtration of macrophages upon intake of alcohol is well known [74, 75]. This results in alteration of adipose tissue accredited to oxidative stress induced by alcohol metabolism [7]. A study indicated that upon chronic alcohol exposure, increased proinflammatory cytokines not only modify the metabolism of adipose tissue but also deregulate adipokine regulation [76].

## 7. Adipokine Regulation upon Alcohol Induction

More than 600 adipokines are secreted from the WAT endocrine organ, which regulates the metabolism of multiple tissues [67]. Among several adipokines, leptin and adiponectin are the major ones which affect the liver.

**7.1. Adiponectin.** It is an adipokine, i.e., anti-inflammatory with insulin sensitizing and adipogenic effects via alteration of AMPK pathway which affects glucose metabolism and fatty acid oxidation in tissues.

The center for ectopic fat storage and lipid storage is through adiponectin. The majority of animal investigations on prolonged alcohol intake show a drop in circulating adiponectin [39, 48, 49, 77–82]. One contradicting study has suggested that the decrease in adiponectin in chronic drinkers (>50 g/day) had no correlation between levels of adiponectin and alcohol intake [83]. Results of adiponectin response in rodents and humans upon alcohol consumption are listed in Table 1. The result discrepancy of/in rodents shows decrease in adiponectin, while in humans' lower doses of alcohol increased adiponectin is species-specific response. A definitive explanation for such a response has not been elucidated.

Potential mechanisms for the decrease of adiponectin in rodents have been identified. In an *in vitro* rat study, VAT cells upon exposure to alcohol MAPK pathway and PPAR $\gamma$  pathway were activated resulting in the decrease of adiponectin secretion [49]. Also, alcohol-treated animals contribute to the impairment of cellular stress and decrease of adiponectin. Alcohol feeding for four days leads to upregula-

tion of CYP2E1 and induction of oxidative stress, including increase of 4-hydroxynonenol (4-HNE) accumulation and a decrease glutathione (GSH/GSSG) ratio [7, 77]. Another investigation presented that intake of 4 weeks of alcohol elevated CHOP mRNA in eWAT and decreased adiponectin [84]. This correlation of ER stress and CHOP may be due to alcohol-induced increase in homocysteine levels, a decline in methylation of S-adenosylmethionine (SAM)/S-adenosylhomocysteine (SAH) ratio and the enzyme cystathionine  $\beta$ -synthase, which is important for the conversion of homocysteine to cysteine in eWAT.

**7.2. Leptin.** Intake of food, energy expenditure, lipolysis, lipogenesis, and fatty acid oxidation are the processes which are regulated by leptin. Since receptors of leptin are present all over the body, it has both paracrine and autocrine functions. Lipid deposition in the liver can be inhibited by activation of  $\beta$ -oxidation of fatty acids by leptin hormone [85]. Circulating leptins are correlated with the alteration in fat mass more than the presence of alcohol. There are contradicting reports on chronic alcohol uptake in rodent models; a few suggested increase in leptin [84, 86, 87] while decrease in leptin is also reported [88, 89] and one study observed no change [84]. Therefore, considering the conflicting findings, no clear pattern or consistencies are derived.

In human studies, serum leptin concentration is not correlated with alcohol intake [90–95]; however, there are few studies which demonstrated conversely [96, 97]. The study reported that the fat mass is directly correlated with the serum leptin levels in alcoholics [96].

Increased leptin protein [75] and mRNA [97–99] within adipose tissue of chronic alcohol-fed rats and mice were observed, while in subcutaneous adipose tissue of alcoholic patients, leptin mRNA remains unaffected. Taking together the above findings, it has been concluded that serum leptin level decreases after administration of ethanol under leptin suppression by adipose tissue into the systemic circulation [100].

**7.3. Resistin.** Adiponectin can be suppressed by resistin and stimulate lipolysis to initiate the release of glycerol and fatty acids in blood circulation [101], while in rodent's chronic alcohol increases serum resistin [102]. Similar results were observed in men, the absence of alcohol for 7 days did not normalize the level of resistin, while alcoholics had little effect in women [103]. In adipose tissue, resistin mRNA expression in rats did not differ, while protein content was increased upon 4 weeks of alcohol induction [102, 104]. Resistin in VAT is increased with 22 weeks of high alcohol feeding (5 g/kg/day), while with lower dose (0.5 and 2.5 g/kg/day) did not alter the resistin level [99]. However, with data being limited, it can be concluded that chronic alcohol is required to raise serum and adipose tissue resistin.

**7.4. Chemerin and Visfatin.** Chemerin is not known for adipokine, but it has important paracrine and autocrine functions in controlling the differentiation and adipogenesis of adipocyte [105]. In studies of the chronic alcohol model of humans and rats, elevation of levels of chemerin is observed

TABLE 1: Adipokine response to consumption of alcohol in rodents and humans.

Model	Effect of alcohol consumption	Reference
Rodent	Decrease in circulating adiponectin	[77]
	Decrease in adiponectin and cartonectin levels	[82, 86, 89, 109–112]
	Increase in leptin, resistin, IL-6, visfatin, chemerin, TNF- $\alpha$ , MCP-1, and RBP-4	[70, 83, 111, 113, 114]
	Decrease leptin	[88, 89]
	Unchanged leptin levels	[99]
	Increase resistin, chemerin, and visfatin	[102, 104, 106]
	Increase in triglyceride gradation and insulin resistance	[115, 116]
	Increase plasma adiponectin in chronic alcohol model	[117–119]
	Decrease plasma leptin in plasma chronic alcohol model	[97, 120, 121]
	Increase in leptin, resistin, and chemerin	[99, 103, 106]
Human	Unchanged leptin and resistin	[90–95, 103]
	Increase in adiponectin, resistin, ghrelin, TNF- $\alpha$ , and IL-6	[43, 48, 70, 78, 122–126]
	Decrease in acylation of stimulating protein	[127]
	Glucose intolerance	[97, 128, 129]




FIGURE 2: Possible treatment strategy to modify gut-adipose tissue-liver axis by the ingestion of probiotic and symbiotic leading to the restoration of gut microbiota.

in both serum and VAT [106]. In men, levels of chemerin are positively correlated with BMI, body fat levels, and triglycerides [106].

Visfatin is associated with adipose tissue glucose metabolism. A study on rats determines a dose-dependent association with alcohol and expression of visfatin levels in serum and VAT [84]. A regular dose of 5 g/kg/day was required to elevate the plasma visfatin concentrations, while a lower dose of 2.5 g/kg/day did not modify visfatin levels in rat serum [107], though the same constant dose for 3 days did decline the plasma peptide levels [108].

Accumulated evidence supports a chronic alcohol effect on the foremost adipokines, i.e., leptin and adiponectin. Conversely, these effects are not coherent while comparing

rodents and humans. The alcohol stimulated modification in adipokine response in various models is presented in Table 1.

A possible treatment strategy to modify gut-adipose tissue-liver axis by the ingestion of probiotic and synbiotic leading to the restoration of gut microbiota is represented in Figure 2.

## 8. Conclusion

Chronic alcohol consumption leads to intestinal dysbiosis in rodents as well as in humans' studies. Altering intestinal barrier function, gut leakiness, triggering proinflammatory cytokines, and pathogenic microbial products



lead to endotoxemia which causes liver injury as well as adipose tissue dysfunction. Metabolic changes in adipocytes lead to an impaired lipolysis, glucose metabolism, TLR4 activation, and adipokine secretion leading to the inflammatory environment. These cascades of adipokines are not exclusive to adipose tissue as it affects hepatic steatosis as well as other tissues all over the body. Till date, research implies that prognosis of ALD can be reduced or prevented by improving the function of adipose tissue and gut. Although considerable development has been made in understanding the adipose tissue metabolism in the presence of alcohol, the exact essential molecular mechanisms connecting adipose tissue injury and development of liver disease upon alcohol ingestion need to be elucidated. Adipokines play a vital role in ALD and drug targeting adipokine, and gut pathways needs to be established and tested for prevention and amelioration of ALD. Therapeutic innervations such as probiotics, prebiotics, synbiotics, or polyphenols may alleviate intestinal microbiota composition with better understanding of the intestinal microbiota homeostasis which may be helpful in preventing the prognosis of ALD.

## Data Availability

The data relevant to the review article is within the manuscript.

## Conflicts of Interest

The authors declare that they have no conflicts of interest.

## References

- [1] WHO, *Global status report on alcohol and health 2018*, WHO, 2019.
- [2] A. Magee, J. Versalovic, and R. A. Luna, "The Gastrointestinal Microbiome," in *Mol. Microbiol.*, pp. 126–137, American Society of Microbiology, 2016.
- [3] R. E. Ley, M. Hamady, C. Lozupone et al., "Evolution of mammals and their gut microbes," *Science*, vol. 320, no. 5883, pp. 1647–1651, 2008.
- [4] M. Wang, X. J. Zhang, K. Feng et al., "Dietary  $\alpha$ -linolenic acid-rich flaxseed oil prevents against alcoholic hepatic steatosis via ameliorating lipid homeostasis at adipose tissue-liver axis in mice," *Scientific Reports*, vol. 6, no. 1, article 26826, 2016.
- [5] W. Zhong, Y. Zhao, Y. Tang et al., "Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis," *The American Journal of Pathology*, vol. 180, no. 3, pp. 998–1007, 2012.
- [6] W. Zhang, W. Zhong, X. Sun et al., "Visceral white adipose tissue is susceptible to alcohol-induced lipodystrophy in rats: role of acetaldehyde," *Alcoholism, Clinical and Experimental Research*, vol. 39, no. 3, pp. 416–423, 2015.
- [7] H. Tang, B. M. Sebastian, A. Axhemi et al., "Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes," *Alcoholism, Clinical and Experimental Research*, vol. 36, no. 2, pp. 214–222, 2012.
- [8] F. M. Souza-Smith, C. H. Lang, L. E. Nagy, S. M. Bailey, L. H. Parsons, and G. J. Murray, "Physiological processes underlying organ injury in alcohol abuse," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 311, pp. E605–E619, 2016.
- [9] E. Mutlu, A. Keshavarzian, P. Engen, C. B. Forsyth, M. Sikaroodi, and P. Gillevet, "Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats," *Alcoholism, Clinical and Experimental Research*, vol. 33, no. 10, pp. 1836–1846, 2009.
- [10] J. C. Bode, C. Bode, R. Heidelberg, H. K. Dürr, and G. A. Martini, "Jejunal microflora in patients with chronic alcohol abuse," 2020, <https://pubmed.ncbi.nlm.nih.gov/6698486/>.
- [11] E. A. Mutlu, P. M. Gillevet, H. Rangwala et al., "Colonic microbiome is altered in alcoholism," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 302, no. 9, pp. G966–G978, 2012.
- [12] A. W. Yan, D. E. Fouts, J. Brandl et al., "Enteric dysbiosis associated with a mouse model of alcoholic liver disease," *Hepatology*, vol. 53, no. 1, pp. 96–105, 2011.
- [13] B. Gao, Y. Duan, S. Lang et al., "Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis," *Hepatology Communications*, vol. 4, no. 8, pp. 1168–1182, 2020.
- [14] Q. Liu, Z. P. Duan, D. K. Ha, S. Bengmark, J. Kurtovic, and S. M. Riordan, "Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis," *Hepatology*, vol. 39, no. 5, pp. 1441–1449, 2004.
- [15] Y. Chen, F. Yang, H. Lu et al., "Characterization of fecal microbial communities in patients with liver cirrhosis," *Hepatology*, vol. 54, no. 2, pp. 562–572, 2011.
- [16] M. I. Queipo-Ortuño, M. Boto-Ordóñez, M. Murri et al., "Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers," *The American Journal of Clinical Nutrition*, vol. 95, no. 6, pp. 1323–1334, 2012.
- [17] F. Guarner and J. R. Malagelada, "Gut flora in health and disease," *The Lancet*, vol. 361, no. 9356, pp. 512–519, 2003.
- [18] C. A. Lozupone, J. I. Stombaugh, J. I. Gordon, J. K. Jansson, and R. Knight, "Diversity, stability and resilience of the human gut microbiota," *Nature*, vol. 489, no. 7415, pp. 220–230, 2012.
- [19] A. Keshavarzian, A. Farhadi, C. B. Forsyth et al., "Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats," *Journal of Hepatology*, vol. 50, no. 3, pp. 538–547, 2009.
- [20] R. K. Rao, A. Seth, and P. Sheth, "Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxemia in alcoholic liver disease," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 286, no. 6, pp. G881–G884, 2004.
- [21] S. Lang, B. Fairfied, B. Gao et al., "Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients," *Gut Microbes*, vol. 12, no. 1, article 1785251, 2020.
- [22] B. Schnabl and D. A. Brenner, "Interactions between the intestinal microbiome and liver diseases," *Gastroenterology*, vol. 146, no. 6, pp. 1513–1524, 2014.
- [23] L. Maccioni, B. Gao, S. Leclercq et al., "Intestinal permeability, microbial translocation, changes in duodenal and fecal

- microbiota, and their associations with alcoholic liver disease progression in humans," *Gut Microbes*, vol. 12, no. 1, article 1782157, 2020.
- [24] H. Chu, L. U. Jiang, B. Gao et al., "The selective PPAR- $\delta$  agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice," *Translational Research*, vol. 227, pp. 1–14, 2021.
  - [25] J. B. Ewaschuk and L. A. Dieleman, "Probiotics and prebiotics in chronic inflammatory bowel diseases," *World Journal of Gastroenterology*, vol. 12, no. 37, pp. 5941–5950, 2006.
  - [26] J. Versalovic, "Probiotics: intestinal gatekeeping, immunomodulation, and hepatic injury," *Hepatology*, vol. 46, no. 3, pp. 618–621, 2007.
  - [27] Y. Tao, K. A. Drabik, T. S. Waypa et al., "Soluble factors from *Lactobacillus* GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells," *American Journal of Physiology-Cell Physiology*, vol. 290, no. 4, pp. C1018–C1030, 2006.
  - [28] Y. Wang, I. Kirpich, Y. Liu et al., "Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury," *The American Journal of Pathology*, vol. 179, no. 6, pp. 2866–2875, 2011.
  - [29] L. Bull-Ottersen, W. Feng, I. Kirpich et al., "Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of lactobacillus rhamnosus GG treatment," *PLoS One*, vol. 8, no. 1, p. e53028, 2013.
  - [30] Y. Wang, Y. Liu, A. Sidhu, Z. Ma, C. McClain, and W. Feng, "Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 303, no. 1, pp. G32–G41, 2012.
  - [31] Y. Wang, Y. Liu, I. Kirpich et al., "Lactobacillus rhamnosus GG reduces hepatic TNF  $\alpha$  production and inflammation in chronic alcohol-induced liver injury," *The Journal of Nutritional Biochemistry*, vol. 24, no. 9, pp. 1609–1615, 2013.
  - [32] M. R. Lakshman, "Some novel insights into the pathogenesis of alcoholic steatosis," *Alcohol*, vol. 34, no. 1, pp. 45–48, 2004.
  - [33] M. R. Lucey, P. Mathurin, and T. R. Morgan, "Alcoholic hepatitis," *The New England Journal of Medicine*, vol. 360, no. 26, pp. 2758–2769, 2009.
  - [34] P. Trayhurn and I. S. Wood, "Adipokines: inflammation and the pleiotropic role of white adipose tissue," *The British Journal of Nutrition*, vol. 92, no. 3, pp. 347–355, 2004.
  - [35] P. Trayhurn and J. H. Beattie, "Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ," *The Proceedings of the Nutrition Society*, vol. 60, no. 3, pp. 329–339, 2001.
  - [36] M. W. Rajala and P. E. Scherer, "Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis," *Endocrinology*, vol. 144, no. 9, pp. 3765–3773, 2003.
  - [37] J. L. Steiner and C. H. Lang, "Alcohol, adipose tissue and lipid dysregulation," *Biomolecules*, vol. 7, no. 4, p. 16, 2017.
  - [38] M. J. Kim, S. Nepal, E. S. Lee, T. C. Jeong, S. H. Kim, and P. H. Park, "Ethanol increases matrix metalloproteinase-12 expression via NADPH oxidase-dependent ROS production in macrophages," *Toxicology and Applied Pharmacology*, vol. 273, no. 1, pp. 77–89, 2013.
  - [39] B. Wang, I. S. Wood, and P. Trayhurn, "Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes," *Pflügers Archiv - European Journal of Physiology*, vol. 455, no. 3, pp. 479–492, 2007.
  - [40] M. A. Abdelmegeed, A. Banerjee, S. Jang et al., "CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis," *Free Radical Biology & Medicine*, vol. 65, pp. 1238–1245, 2013.
  - [41] A. Banerjee, M. A. Abdelmegeed, S. Jang, and B.-J. Song, "Increased sensitivity to binge alcohol-induced gut leakiness and inflammatory liver disease in HIV transgenic rats," *PLoS One*, vol. 10, no. 10, article e0140498, 2015.
  - [42] S. Patel, R. Behara, G. R. Swanson, C. B. Forsyth, R. M. Voigt, and A. Keshavarzian, "Alcohol and the intestine," *Biomolecules*, vol. 5, no. 4, pp. 2573–2588, 2015.
  - [43] C. Zhao, Y. Liu, J. Xiao et al., "FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice," *Journal of Lipid Research*, vol. 56, no. 8, pp. 1481–1491, 2015.
  - [44] L. Kang, X. Chen, B. M. Sebastian et al., "Chronic ethanol and triglyceride turnover in white adipose tissue in rats: inhibition of the anti-lipolytic action of insulin after chronic ethanol contributes to increased triglyceride degradation," *The Journal of Biological Chemistry*, vol. 282, no. 39, pp. 28465–28473, 2007.
  - [45] T. Inagaki, P. Dutchak, G. Zhao et al., "Endocrine regulation of the fasting response by PPAR $\alpha$ -mediated induction of fibroblast growth factor 21," *Cell Metabolism*, vol. 5, no. 6, pp. 415–425, 2007.
  - [46] K. T. Crowell, J. L. Steiner, C. S. Coleman, and C. H. Lang, "Decreased whole-body fat mass produced by chronic alcohol consumption is associated with activation of S6K1-mediated protein synthesis and increased autophagy in epididymal white adipose tissue," *Alcoholism, Clinical and Experimental Research*, vol. 40, no. 9, pp. 1832–1845, 2016.
  - [47] X. Sun, Y. Tang, X. Tan et al., "Activation of peroxisome proliferator-activated receptor- $\gamma$  by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 302, no. 5, pp. G548–G557, 2012.
  - [48] H.-I. Lee and M.-K. Lee, "Coordinated regulation of scopoletin at adipose tissue-liver axis improved alcohol-induced lipid dysmetabolism and inflammation in rats," *Toxicology Letters*, vol. 237, no. 3, pp. 210–218, 2015.
  - [49] C. Tian, X. Jin, X. Ye et al., "Long term intake of 0.1% ethanol decreases serum adiponectin by suppressing PPAR $\gamma$  expression via p 38 MAPK pathway," *Food and Chemical Toxicology*, vol. 65, pp. 329–334, 2014.
  - [50] P. Trayhurn, B. Wang, and I. S. Wood, "Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?," *The British Journal of Nutrition*, vol. 100, no. 2, pp. 227–235, 2008.
  - [51] N. Hosogai, A. Fukuhara, K. Oshima et al., "Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation," *Diabetes*, vol. 56, no. 4, pp. 901–911, 2007.
  - [52] F. M. Souza-Smith, L. Simon, R. Siggins, and P. E. Molina, "Alcohol-induced mesenteric lymphatic permeability: link to immunometabolic modulation of perilymphatic adipose tissue," *International Journal of Molecular Sciences*, vol. 20, no. 17, p. 4097, 2019.
  - [53] R. Cuddy and G. Li, "The role of alcohol in asthma: a review of clinical and experimental studies," *The American Journal of Emergency Medicine*, vol. 19, no. 6, pp. 501–503, 2001.

- [54] N. A. Gonzaga, G. E. Callera, A. Yogi et al., "Acute ethanol intake induces mitogen-activated protein kinase activation, platelet-derived growth factor receptor phosphorylation, and oxidative stress in resistance arteries," *Journal of Physiology and Biochemistry*, vol. 70, no. 2, pp. 509–523, 2014.
- [55] J. A. Simplicio, N. A. Gonzaga, M. A. Nakashima et al., "Tumor necrosis factor- $\alpha$  receptor 1 contributes to ethanol-induced vascular reactive oxygen species generation and hypertension," *Journal of the American Society of Hypertension*, vol. 11, no. 10, pp. 684–696.e3, 2017.
- [56] N. A. Gonzaga, W. M. C. Awata, G. T. do Vale et al., "Perivascular adipose tissue protects against the vascular dysfunction induced by acute ethanol intake: role of hydrogen peroxide," *Vascular Pharmacology*, vol. 111, pp. 44–53, 2018.
- [57] R. M. Touyz and A. M. Briones, "Reactive oxygen species and vascular biology: implications in human hypertension," *Hypertension Research*, vol. 34, no. 1, pp. 5–14, 2011.
- [58] A. Yogi, G. E. Callera, A. S. Mecawi et al., "Acute ethanol intake induces superoxide anion generation and mitogen-activated protein kinase phosphorylation in rat aorta: a role for angiotensin type 1 receptor," *Toxicology and Applied Pharmacology*, vol. 264, no. 3, pp. 470–478, 2012.
- [59] M. Löhn, G. Dubrovskaya, B. Lauterbach, F. C. Luft, M. Gollasch, and A. M. Sharma, "Periadventitial fat releases a vascular relaxing factor," *The FASEB Journal*, vol. 16, no. 9, pp. 1057–1063, 2002.
- [60] S. Verlohren, G. Dubrovskaya, S. Y. Tsang et al., "Visceral periaortic adipose tissue regulates arterial tone of mesenteric arteries," *Hypertension*, vol. 44, no. 3, pp. 271–276, 2004.
- [61] Y.-J. Gao, "Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular dysfunction," *Current Pharmaceutical Design*, vol. 13, no. 21, pp. 2185–2192, 2007.
- [62] Y. J. Gao, K. Takemori, L. Y. Su et al., "Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion," *Cardiovascular Research*, vol. 71, no. 2, pp. 363–373, 2006.
- [63] K. N. Frayn, S. W. Coppack, P. E. Walsh, H. C. Butterworth, S. M. Humphreys, and H. C. Pedrosa, "Metabolic responses of forearm and adipose tissues to acute ethanol ingestion," *Metabolism*, vol. 39, no. 9, pp. 958–966, 1990.
- [64] M. F. Shih and P. V. Taberner, "Effects of acute and chronic ethanol administration on the response of mouse adipose tissue hormone-sensitive lipase to  $\alpha$ 2-ADRENOCEPTOR activation by UK 14304," *Alcohol and Alcoholism*, vol. 36, no. 5, pp. 381–387, 2001.
- [65] M.-F. Shih and P. V. Taberner, "Changes in adipose tissue hormone-sensitive lipase activity and cAMP during ethanol withdrawal," *European Journal of Pharmacology*, vol. 409, no. 3, pp. 223–231, 2000.
- [66] M. F. Shih and P. V. Taberner, "Dose-dependent effects of chronic ethanol on mouse adipose tissue lipase activity and cyclic AMP accumulation," *British Journal of Pharmacology*, vol. 120, no. 4, pp. 721–727, 1997.
- [67] Z. Shen, X. Liang, C. Q. Rogers, D. Rideout, and M. You, "Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 298, no. 3, pp. G364–G374, 2010.
- [68] L. A. Woollett, G. L. Baldner-Shank, S. Aprahamian, R. L. Engen, and D. C. Beitz, "Adaptation of lipogenesis and lipolysis to dietary ethanol," *Alcoholism, Clinical and Experimental Research*, vol. 11, pp. 336–339, 1987.
- [69] X. Chen, B. M. Sebastian, and L. E. Nagy, "Chronic ethanol feeding to rats decreases adiponectin secretion by subcutaneous adipocytes," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 292, no. 2, article E621, E628 pages, 2007.
- [70] B. M. Sebastian, S. Roychowdhury, H. Tang et al., "Identification of a cytochrome P4502E1/Bid/C1q-dependent axis mediating inflammation in adipose tissue after chronic ethanol feeding to mice," *The Journal of Biological Chemistry*, vol. 286, no. 41, pp. 35989–35997, 2011.
- [71] M. A. Barnes, M. R. McMullen, S. Roychowdhury et al., "Macrophage migration inhibitory factor contributes to ethanol-induced liver injury by mediating cell injury, steatohepatitis, and steatosis," *Hepatology*, vol. 57, no. 5, pp. 1980–1991, 2013.
- [72] M. A. Barnes, S. Roychowdhury, and L. E. Nagy, "Innate immunity and cell death in alcoholic liver disease: role of cytochrome P4502E1," *Redox Biology*, vol. 2, pp. 929–935, 2014.
- [73] T. Kumagi, F. Akbar, N. Horiike, and M. Onji, "Increased serum levels of macrophage migration inhibitory factor in alcoholic liver diseases and their expression in liver tissues," *Clinical Biochemistry*, vol. 34, no. 3, pp. 189–193, 2001.
- [74] C. Q. Rogers, J. M. Ajmo, and M. You, "Adiponectin and alcoholic fatty liver disease," *IUBMB Life*, vol. 60, no. 12, pp. 790–797, 2008.
- [75] J. M. Nicolas, J. Fernandez-Sola, F. Fatjo et al., "Increased circulating leptin levels in chronic alcoholism," *Alcoholism, Clinical and Experimental Research*, vol. 25, no. 1, pp. 83–88, 2001.
- [76] G. R. Hajer, T. W. Van Haeften, and F. L. J. Visseren, "Adipose tissue dysfunction in obesity, diabetes, and vascular diseases," *European Heart Journal*, vol. 29, no. 24, pp. 2959–2971, 2008.
- [77] X. Chen, B. M. Sebastian, H. Tang et al., "Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats," *Hepatology*, vol. 49, no. 5, pp. 1554–1562, 2009.
- [78] A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. L. Lam, and G. J. S. Cooper, "The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice," *The Journal of Clinical Investigation*, vol. 112, no. 1, pp. 91–100, 2003.
- [79] Z. Song, Z. Zhou, I. Deaciuc, T. Chen, and C. J. McClain, "Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease," *Hepatology*, vol. 47, no. 3, pp. 867–879, 2008.
- [80] S. M. Ford, L. Simon, C. Vande Stouwe et al., "Chronic binge alcohol administration impairs glucose-insulin dynamics and decreases adiponectin in asymptomatic simian immunodeficiency virus-infected macaques," *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, vol. 311, no. 5, pp. R888–R897, 2016.
- [81] V. Thakur, M. T. Pritchard, M. R. McMullen, and L. E. Nagy, "Adiponectin normalizes LPS-stimulated TNF- $\alpha$  production by rat Kupffer cells after chronic ethanol feeding," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 290, no. 5, pp. G998–G1007, 2006.
- [82] F. Esfandiari, M. You, J. A. Villanueva, D. H. Wong, S. W. French, and C. H. Halsted, "S-Adenosylmethionine



- attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet," *Alcoholism, Clinical and Experimental Research*, vol. 31, no. 7, pp. 1231–1239, 2007.
- [83] S. K. Jung, M. K. Kim, J. Shin, and B. Y. Choi, "A cross-sectional analysis of the relationship between daily alcohol consumption and serum adiponectin levels among adults aged 40 years or more in a rural area of Korea," *European Journal of Clinical Nutrition*, vol. 67, no. 8, pp. 841–847, 2013.
- [84] H. C. Yu, S. Y. Li, M. F. Cao et al., "Effects of chronic ethanol consumption on levels of adipokines in visceral adipose tissues and sera of rats," *Acta Pharmacologica Sinica*, vol. 31, no. 4, pp. 461–469, 2010.
- [85] J. H. Stern, J. M. Rutkowski, and P. E. Scherer, "Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk," *Cell Metabolism*, vol. 23, no. 5, pp. 770–784, 2016.
- [86] T. Szkudelski, I. Bialik, and K. Szkudelska, "Adipocyte lipolysis, hormonal and metabolic changes in ethanol-drinking rats," *Journal of Animal Physiology and Animal Nutrition*, vol. 88, no. 7-8, pp. 251–258, 2004.
- [87] T. Obradovic and G. G. Meadows, "Chronic ethanol consumption increases plasma leptin levels and alters leptin receptors in the hypothalamus and the perigonadal fat of C57BL/6 mice," *Alcoholism: Clinical and Experimental Research*, vol. 26, no. 2, pp. 255–262, 2002.
- [88] X. Tan, X. Sun, Q. Li et al., "Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver disease in mice," *The American Journal of Pathology*, vol. 181, no. 4, pp. 1279–1286, 2012.
- [89] J. K. Hiney, F. L. Dearth RK III, S. Wood, V. Srivastava, and W. L. Dees, "Effects of ethanol on leptin secretion and the leptin-induced luteinizing hormone (LH) release from late juvenile female rats," *Alcoholism, Clinical and Experimental Research*, vol. 23, no. 11, pp. 1785–1792, 1999.
- [90] J. W. J. Beulens, E. C. de Zoete, F. J. Kok, G. Schaafsma, and H. F. J. Hendriks, "Effect of moderate alcohol consumption on adipokines and insulin sensitivity in lean and overweight men: a diet intervention study," *European Journal of Clinical Nutrition*, vol. 62, no. 9, pp. 1098–1105, 2008.
- [91] C. S. Voican, M. Njiké-Nakseu, H. Boujedidi et al., "Alcohol withdrawal alleviates adipose tissue inflammation in patients with alcoholic liver disease," *Liver International*, vol. 35, no. 3, pp. 967–978, 2015.
- [92] K. Marta, Z. Tomáš, P. Petr et al., "Advanced glycation end-products in patients with chronic alcohol misuse," *Alcohol and Alcoholism*, vol. 39, no. 4, pp. 316–320, 2004.
- [93] S. G. Wannamethee, J. Tchernova, P. Whincup et al., "Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease," *Atherosclerosis*, vol. 191, no. 2, pp. 418–426, 2007.
- [94] P. Lagiou, L. B. Signorello, C. S. Mantzoros, D. Trichopoulos, C. Hsieh, and A. Trichopoulou, "Hormonal, lifestyle, and dietary factors in relation to leptin among elderly men," *Annals of Nutrition & Metabolism*, vol. 43, no. 1, pp. 23–29, 1999.
- [95] A. De Silva, M. De Courten, P. Zimmet et al., "Lifestyle factors fail to explain the variation in plasma leptin concentrations in women," *Nutrition*, vol. 14, no. 9, pp. 653–657, 1998.
- [96] F. Santolària, A. Pérez-Cejas, M. R. Alemán et al., "Low serum leptin levels and malnutrition in chronic alcohol misusers hospitalized by somatic complications," *Alcohol and Alcoholism*, vol. 38, no. 1, pp. 60–66, 2003.
- [97] R. P. Donahue, P. Zimmet, J. A. Bean et al., "Cigarette smoking, alcohol use, and physical activity in relation to serum leptin levels in a multiethnic population: the Miami community health study," *Annals of Epidemiology*, vol. 9, no. 2, pp. 108–113, 1999.
- [98] S. Naveau, A.-M. Cassard-Doulcier, M. Njiké-Nakseu et al., "Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease," *Journal of Hepatology*, vol. 52, no. 6, pp. 895–902, 2010.
- [99] J. H. Henriksen, J. J. Holst, S. Møller, K. Brinch, and F. Bendtsen, "Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal," *Hepatology*, vol. 29, no. 6, pp. 1818–1824, 1999.
- [100] M. Otake, N. Konishi, M. Odashima et al., "Effect of alcohol consumption on leptin level in serum, adipose tissue, and gastric mucosa," *Digestive Diseases and Sciences*, vol. 52, no. 11, pp. 3066–3069, 2007.
- [101] N. Chen, L. Zhou, Z. Zhang, J. Xu, Z. Wan, and L. Qin, "Resistin induces lipolysis and suppresses adiponectin secretion in cultured human visceral adipose tissue," *Regulatory Peptides*, vol. 194-195, pp. 49–54, 2014.
- [102] E. Pravdova, L. Macho, and M. Fickova, "Alcohol intake modifies leptin, adiponectin and resistin serum levels and their mRNA expressions in adipose tissue of rats," *Endocrine Regulations*, vol. 43, no. 3, pp. 117–125, 2009.
- [103] T. Hillemacher, C. Weinland, A. Heberlein et al., "Increased levels of adiponectin and resistin in alcohol dependence—possible link to craving," *Drug and Alcohol Dependence*, vol. 99, no. 1-3, pp. 333–337, 2009.
- [104] E. Pravdová, L. Macho, N. Hlaváčová, and M. Ficková, "Long-time alcohol intake modifies resistin secretion and expression of resistin gene in adipose tissue," *General Physiology and Biophysics*, vol. 26, no. 3, pp. 221–229, 2007.
- [105] K. B. Goralski, T. C. McCarthy, E. A. Hanniman et al., "Chemerin, a Novel Adipokine That Regulates Adipogenesis and Adipocyte Metabolism\*," *The Journal of Biological Chemistry*, vol. 282, no. 38, pp. 28175–28188, 2007.
- [106] R. Z. Ren, X. Zhang, J. Xu et al., "Chronic ethanol consumption increases the levels of chemerin in the serum and adipose tissue of humans and rats," *Acta Pharmacologica Sinica*, vol. 33, no. 5, pp. 652–659, 2012.
- [107] F. M. Souza-Smith, R. W. Siggins, and P. E. Molina, "Mesenteric lymphatic-perilymphatic adipose crosstalk: role in alcohol-induced perilymphatic adipose tissue inflammation," *Alcoholism, Clinical and Experimental Research*, vol. 39, no. 8, pp. 1380–1387, 2015.
- [108] F. M. Souza-Smith, S. M. Ford, L. Simon, and P. E. Molina, "Repeated binge-like alcohol intoxication: depot-specific adipose tissue Immuno-metabolic dysregulation," *Shock*, vol. 48, no. 2, pp. 243–250, 2017.
- [109] E. D. Abel, O. Peroni, J. K. Kim et al., "Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver," *Nature*, vol. 409, no. 6821, pp. 729–733, 2001.
- [110] F. Marra and C. Bertolani, "Adipokines in liver diseases," *Hepatology*, vol. 50, no. 3, pp. 957–969, 2009.
- [111] D. B. Savage, C. P. Sewter, E. S. Klenk et al., "Resistin/fizz 3 expression in relation to obesity and peroxisome proliferator-activated receptor- $\gamma$  action in humans," *Diabetes*, vol. 50, no. 10, pp. 2199–2202, 2001.
- [112] Y. Qin, J. L. Hamilton, M. D. Bird et al., "Adipose inflammation and macrophage infiltration after binge ethanol and

- burn injury," *Alcoholism, Clinical and Experimental Research*, vol. 38, no. 1, pp. 204–213, 2014.
- [113] L. Kang and L. E. Nagy, "Chronic ethanol feeding suppresses  $\beta$ -adrenergic receptor-stimulated lipolysis in adipocytes isolated from epididymal fat," *Endocrinology*, vol. 147, no. 9, pp. 4330–4338, 2006.
- [114] H. Yki-Jarvinen, V. A. Koivisto, R. Ylikahri, and M. R. Taskinen, "Acute effects of ethanol and acetate on glucose kinetics in normal subjects," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 254, no. 2, pp. E175–E180, 1988.
- [115] N. Rachdaoui, B. M. Sebastian, and L. E. Nagy, "Chronic ethanol feeding impairs endothelin-1-stimulated glucose uptake via decreased  $G\alpha_{11}$  expression in rat adipocytes," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 285, no. 2, pp. E303–E310, 2003.
- [116] X. Wei, X. Shi, W. Zhong et al., "Chronic alcohol exposure disturbs lipid homeostasis at the adipose tissue-liver axis in mice: analysis of triacylglycerols using high-resolution mass spectrometry in combination with in vivo metabolite deuterium labeling," *PLoS One*, vol. 8, no. 2, article e55382, 2013.
- [117] S. L. Zhou, R. E. Gordon, M. Bradbury, D. Stump, C. L. Kiang, and P. D. Berk, "Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in HepG2 cells," *Hepatology*, vol. 27, no. 4, pp. 1064–1074, 1998.
- [118] P. D. Berk, S. Zhou, and M. W. Bradbury, "Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings," *Transactions of the American Clinical and Climatological Association*, vol. 116, pp. 335–44; discussion 345, 2005, discussion 345.
- [119] S. Galic, J. S. Oakhill, and G. R. Steinberg, "Adipose tissue as an endocrine organ," *Molecular and Cellular Endocrinology*, vol. 316, no. 2, pp. 129–139, 2010.
- [120] Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, "Positional cloning of the mouse *obese* gene and its human homologue," *Nature*, vol. 372, no. 6505, pp. 425–432, 1994.
- [121] S. R jdmark, J. Calissendorff, and K. Brismar, "Alcohol ingestion decreases both diurnal and nocturnal secretion of leptin in healthy individuals," *Clinical Endocrinology*, vol. 55, no. 5, pp. 639–647, 2001.
- [122] G. Addolorato, E. Capristo, A. V. Greco, G. F. Stefanini, and G. Gasbarrini, "Influence of chronic alcohol abuse on body weight and energy metabolism: is excess ethanol consumption a risk factor for obesity or malnutrition?," *Journal of Internal Medicine*, vol. 244, no. 5, pp. 387–395, 1998.
- [123] A. Sierksma, H. Patel, N. Ouchi et al., "Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor- $\alpha$ , and insulin sensitivity," *Diabetes Care*, vol. 27, no. 1, pp. 184–189, 2004.
- [124] M. M. Joosten, J. W. J. Beulens, S. Kersten, and H. F. J. Hendriks, "Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression in postmenopausal women: a randomised, crossover trial," *Diabetologia*, vol. 51, no. 8, pp. 1375–1381, 2008.
- [125] L. A. Poirier, N. Rachdaoui, and L. E. Nagy, "GLUT4 vesicle trafficking in rat adipocytes after ethanol feeding: regulation by heterotrimeric G-proteins," *The Biochemical Journal*, vol. 354, no. 2, pp. 323–330, 2001.
- [126] A. Wandler, J. M. Bruun, M. P. Nielsen, and B. Richelsen, "Ethanol exerts anti-inflammatory effects in human adipose tissue in vitro," *Molecular and Cellular Endocrinology*, vol. 296, no. 1–2, pp. 26–31, 2008.
- [127] L. E.  gge, M. D. Gerhard Brohall, M. D. Carl Johan Behre, C. Schmidt, and B. Fagerberg, "Alcohol consumption in relation to metabolic regulation, inflammation, and adiponectin in 64-year-old caucasian women: a population-based study with a focus on impaired glucose regulation," *Diabetes Care*, vol. 29, no. 4, pp. 908–913, 2006.
- [128] P. M. Suter, Y. Schutz, and E. Jequier, "The effect of ethanol on fat storage in healthy subjects," *The New England Journal of Medicine*, vol. 326, no. 15, pp. 983–987, 1992.
- [129] J. W. Beulens, L. J. van Loon, F. J. Kok et al., "The effect of moderate alcohol consumption on adiponectin oligomers and muscle oxidative capacity: a human intervention study," *Diabetologia*, vol. 50, no. 7, pp. 1388–1392, 2007.

## Research Article

# Prophylactic Treatment of Probiotic and Metformin Mitigates Ethanol-Induced Intestinal Barrier Injury: *In Vitro*, *In Vivo*, and *In Silico* Approaches

Farhin Patel <sup>1</sup>, Kirti Parwani <sup>1</sup>, Priyashi Rao <sup>2</sup>, Dhara Patel <sup>1</sup>, Rakesh Rawal <sup>2</sup>, and Palash Mandal <sup>1</sup>

<sup>1</sup>Department of Biological Sciences, P.D. Patel Institute of Applied Sciences, Charotar University of Science and Technology, Changa, 388421 Anand, Gujarat, India

<sup>2</sup>Department of Biochemistry & Forensic Science, University School of Sciences, Gujarat University, Ahmedabad, 380009 Gujarat, India

Correspondence should be addressed to Palash Mandal; [palashmandal.bio@charusat.ac.in](mailto:palashmandal.bio@charusat.ac.in)

Received 18 May 2021; Accepted 9 August 2021; Published 27 September 2021

Academic Editor: Sanjoy Roychowdhury

Copyright © 2021 Farhin Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ethanol depletes intestinal integrity and promotes gut dysbiosis. Studies have suggested the individual role of probiotics and metformin Met in protecting intestinal barrier function from injuries induced by ethanol. The objective of the current study is to investigate the potential mechanism by which coadministration of probiotic Visbiome® (V) and Met blocks the ethanol-induced intestinal barrier dysfunction/gut leakiness utilizing Caco-2 monolayers, a rat model with chronic ethanol injury, and *in silico* docking interaction models. In Caco-2 monolayers, exposure to ethanol significantly disrupted tight junction (TJ) localization, elevated monolayer permeability, and oxidative stress compared with controls. However, cotreatment with probiotic V and Met largely ameliorated the ethanol-induced mucosal barrier dysfunction, TJ disruption, and gut oxidative stress compared with ethanol-exposed monolayers and individual treatment of either agent. Rats fed with ethanol-containing Lieber-DeCarli liquid diet showed decreased expression of TJ proteins, and increased intestinal barrier injury resulting in pro-inflammatory response and oxidative stress in the colon. We found that co-administration of probiotic V and Met improved the expression of intestinal TJ proteins (ZO-1 and occludin) and upregulated the anti-inflammatory response, leading to reduced ER stress. Moreover, co-administration of probiotic V and Met inhibited the CYP2E1 and NOX gene expression, and increase the translocation of Nrf-2 as well as anti-oxidative genes (SOD, catalase, Gpx, and HO-1), leading to reduced colonic ROS content and malondialdehyde levels. The combined treatment of probiotic V and Met also improved their binding affinities towards HO-1, Nrf-2, SLC5A8, and GPR109A, which could be attributed to their synergistic effect. Our findings based on *in-vitro*, *in-vivo*, and *in-silico* analyses suggest that the combination of probiotic V and Met potentially acts in synergism, attributable to their property of inhibition of inflammation and oxidative stress against ethanol-induced intestinal barrier injury.

## 1. Introduction

Chronic alcohol consumption is associated with numerous gastrointestinal and liver disorders, especially alcoholic liver disease (ALD) [1]. While the precise molecular mechanism of ALD pathogenesis is not fully understood, few of the reports suggested that ethanol-induced barrier dysfunction plays a crucial role in ALD progression [2, 3]. Intestinal epi-

thelial tight junctions (TJs) are considered to be the key regulators of intestinal mucosal permeability [4]; therefore, regulating the TJ protein expression (i.e., occludin, claudins, and zonula occludens (ZO)) or modulating its functions will positively influence intestinal barrier function. Alcohol consumption is known to disrupt TJs resulting in increased intestinal permeability [5]. It is now a most likely accepted fact that impaired intestinal epithelial integrity and intestinal

barrier dysfunction are the two principle reasons behind the increased intestinal permeability [6]. Studies have indicated that alcohol-induced increased intestinal permeability leads to an anomalous leakage of bacterial endotoxins, thereby causing liver damage [7]. In alcoholics, increased blood endotoxin levels (endotoxemia) can be due to three potential mechanisms: (i) due to both abnormal gut dysbiosis and overproduction of bacteria leading to increased endotoxin production; (ii) due to gut leakiness, which causes increased endotoxin permeation through the gut; and (iii) due to either portal hypertension or Kupffer cell dysfunction leading to decreased endotoxin elimination [8, 9]. When there is no evidence of portal hypertension and defective Kupffer's cell function, then it is not considered as an important factor in the initiation of ALD [8]. Therefore, gut leakiness or disrupted intestinal barrier function is considered to be the important mechanism for ethanol-induced increased endotoxemia in alcohol-mediated liver injury [10].

Equally unclear is the molecular mechanism mediating ethanol-induced gut leakiness. Several lines of evidence suggest that the culprit is ethanol-induced tissue oxidative stress. Studies showed that alcohol disrupts the barrier integrity of monolayers of intestinal cells and that alcohol-induced disruption is due to oxidative injury to the cytoskeleton [11]. CYP2E1, an enzyme playing an important role in alcohol metabolism, may contribute to alcohol-induced intestinal effects [12]. Oxidative stress and ROS are predominantly generated through the induction of CYP2E1 metabolism that may perhaps facilitate the disruption of intestinal permeability [13]. The challenge to treat any stage of ALD other than by abstinence still lies in the incapability to recognize new therapeutic strategies. Therefore, studies showed that a better understanding of the exact molecular mechanisms responsible for the ethanol-induced increase in intestinal permeability may eventually result in more effective prevention/treatment strategies for inhibiting the progression of ALD [14].

The intestinal bacterium that refers to gut microbiota has a reflective impact on the host metabolism and its immune system [15]. Indeed, intestinal bacteria contribute to the expansion of the intestinal architecture and immune system and also play a lead role in gut barrier function maintenance [16]. Among all the beneficial functions of gut microbiota, its capability to ferment long-chain polysaccharides that avoid human metabolism producing short-chain fatty acids (SCFAs) is considered to be the best characteristic. The predominant SCFAs produced are acetate, propionate, and butyrate [17]. Among the three SCFAs, butyrate is present to a smaller extent, but is the most effective. After ethanol consumption, the SCFA levels in the intestine were noted to be decreased, except for acetate, whose levels are known to be increased as it is the metabolite of ethanol [18].

Modulation of gut microbiota through probiotic administration is considered to be one of the optimized formulations towards alcohol-induced gut injury. According to a World Health Organization (WHO)/Food and Agriculture Organization (FAO) report, probiotics are live microorganisms that when used in suitable quantities, confer a health

benefit on the host improving the functional properties of gut microbiota [19]. In the past years, emerging concepts for the use of probiotics as functional products have been observed in preventing the ethanol-induced disruption of colonic epithelial TJs and barrier dysfunction [20]. Additionally, an *in vivo* study explained that the probiotic *Lactobacillus rhamnosus* GG (LGG) helps in reducing gut permeability, oxidative stress, and inflammation in the liver and intestine [21].

Met is another such medicinal compound known to possess anti-hyperglycemic activity that has a potential to prevent alcohol-induced liver injury [22]. Recent studies have revealed that (Met) exerts a constructive role in attenuating intestinal dysbiosis. In type 2 diabetes, Met has been known to alleviate the gut microbiota imbalance partially [23]. Studies also demonstrated the role of Met in preventing the intestinal mucosal barrier injury and inflammation caused by dextran sulfate sodium (DSS) [24]. In LPS-induced *in-vitro* and *in vivo* models, Met alleviates the intestinal TJ dysfunction, oxidative stress, and inflammatory response [25].

Since intestinal injury is associated with oxidative stress and free radical formation, compounds with antioxidant properties could act as an inhibitor in ameliorating ethanol-induced intestinal injury. Considering the above experimental studies as well as the individual protective role of probiotics and Met towards intestinal homeostasis, the current study was executed to investigate the potential combinatorial role of probiotic V and Met in preventing the increased intestinal barrier integrity, epithelial cell permeability, and butyrate levels through interactions with receptors and transporters by inhibiting the gut oxidative stress and inflammation in ethanol-induced intestinal injury (*in vitro* and *in vivo* models of intestinal injury). To know and understand the plausible mechanism by which combined treatment of probiotic V and Met could act in synergism to prevent oxidative stress and to maintain intestinal permeability induced by ethanol, we adopted an *in silico* approach and performed the docking of Met and butyrate (metabolite released from probiotic V) with antioxidants, i.e., Nrf-2 and HO-1 as well as butyrate sensors, i.e., the butyrate receptor GPR109A and the butyrate transporter SLC5A8.

## 2. Materials and Methods

**2.1. Materials.** All chemicals were purchased from HiMedia Laboratories (HiMedia Laboratories Private Limited, India) unless cited otherwise. The TRIzol Reagent, cDNA Synthesis Kit, and SYBR/ROX Master Mix were purchased from Thermo Fisher Scientific (USA). The metformin reagent and primers for quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) were obtained from Sigma-Aldrich (USA).

**2.2. Cell Culture.** In the present study, a human colonic epithelial cell line, i.e., Caco-2 cells, were acquired from the National Centre for Cell Sciences (NCCS), Pune, India, and were cultured in dulbecco's modified eagle medium (DMEM) medium supplemented with 20% (v/v) fetal bovine



serum (FBS) and 1% (v/v) antibiotic-antimycotic solution in a humidified atmosphere of 5% (v/v) CO<sub>2</sub> at 37°C. The experimental dose of probiotic V and Met (i.e., 10 µl and 1 mM, along with 100 mM ethanol) was previously determined in our lab using an MTT cytotoxicity assay [26]. Cells were maintained in T75 flasks, and the medium was replaced every second day for 23 days. After attaining 70% confluency, cells were detached by using a 0.25% trypsin-EDTA solution for about 5 min, then centrifuged at 1000 rpm for 5 min, removed the supernatant, resuspended in 16 mL of complete medium (DMEM), and seeded equally into two new T75 flasks. Cells from passages 30 to 38 were used for all experiments.

**2.3. Probiotic Visbiome® Supplementation in an In Vitro and In Vivo Model of Intestinal Barrier Injury.** Visbiome® (Lot #07197721) is considered to be a probiotic mixture of three viable lyophilized bacterial species containing  $112.5 \times 10^9$  CFU/capsule. The consortium includes four strains of lactobacilli (*Lactobacillus acidophilus*, *Lactobacillus paracasei*, *Lactobacillus delbrueckii* subspecies *bulgaricus*, and *Lactobacillus plantarum*), three strains of bifidobacteria (*Bifidobacterium longum*, *Bifidobacterium infantis*, and *Bifidobacterium breve*), and *Streptococcus salivarius* subspecies *thermophilus*. Probiotic Visbiome® (V) containing 1 g of each stock was suspended in the De Man, Rogosa, and Sharpe agar (MRS) broth (pH:  $6.5 \pm 0.2$ ) at 25°C to activate the probiotic V culture. The probiotic V stock culture was conserved through a glycerol-MRS broth at a concentration of 20% (v/v) and maintained at -70°C.

**2.3.1. For In Vitro Supplementation.** The probiotic V culture was sonicated for 30 min (repeating 10 s of sonication and 10 s of hold) with a sonicator. The probiotic V bacterial culture at its respective final concentration was centrifuged at  $1500 \times g$  for 10 min and the individual supernatant (whole-cell extract) was obtained. Furthermore, the obtained supernatant was centrifuged at  $6500 \times g$  for 30 min yielding the cell cytosol (supernatant) and the membrane (pellet). The cell-free supernatant was stored at -20°C and used for further experimentation.

**2.3.2. For In Vivo Supplementation.** The probiotic V (1%) culture was inoculated into another freshly prepared MRS broth. The probiotic V inoculum was collected by centrifugation at  $10,000 \times g$  and 4°C for 10 min. After centrifugation, the remaining cell pellet was washed thrice with phosphate-buffered saline (PBS). Then, the cell pellet was resuspended in sterile distilled water with  $10^8$  colony-forming unit (CFU)/ml as a final concentration for further experimental use.

**2.4. Animals.** Eight- to ten-week-old male Wistar rats weighing 200–225 g were acquired from Zydus Pharmaceutical Industries Pvt. Ltd. (India). Rats were allowed to acclimatize in standard cages (two rat/cage) and were fed a normal chow diet under ambient conditions (temperature:  $22 \pm 2^\circ\text{C}$ ; relative humidity:  $55 \pm 5\%$ ) with a 12 h light and 12 h dark cycle before the commencement of the feeding experiment with the Lieber DeCarli liquid diet.

## 2.5. In Vitro and In Vivo Induction of Intestinal Barrier Injury Using Ethanol Stimulation with Simultaneous Probiotic Visbiome® and Metformin Administration

**2.5.1. In Vitro Model.** Caco-2 cells were seeded in 6-well plates at the seeding density of  $1.8 \times 10^5$  cells/ml and cultured for 23 days. Later, we assigned Caco-2 monolayers into the following groups: (a) the control group of untreated Caco-2 monolayers; (b) the ethanol group—cells were treated with serum-free 100 mM ethanol-containing medium for 48 h to induce intestinal epithelial barrier dysfunction; (c) experimental group-1—cells were treated with serum-free medium containing 1 mM Met concentration along with 100 mM ethanol for 48 h; (d) experimental group-2—cells were treated with serum-free medium containing 10 µl/ml probiotic V along with 100 mM ethanol for 48 h; and (e) experimental group-3 with the combination—cells were treated with serum-free medium containing 1 mM Met and 10 µl/ml probiotic V along with 100 mM ethanol for 48 h.

**2.5.2. In Vivo Model.** Weight and age-matched rats were given Liber DeCarli's diet for the first 2 days for acclimatization. After 2 days, ethanol-fed rats were permitted free access to a complete ethanol-containing Lieber DeCarli diet. Also, control rats were given a pair-fed diet containing maltodextrin (substituted isocalorically) for the entire feeding period. The ethanol-induced intestinal barrier injury model (25 days, 32% total calories) contained increased concentrations of ethanol (vol/vol): 1% (2 days), 2% (2 days), 4% (7 days), 5% (7 days), and lastly 6% (7 days) [26].

Oral supplementation of probiotic V and Met was given at doses of  $10^8$  CFU/day and 75 mg/kg, respectively, to the experimental rats [26]. Following ethanol exposure protocols, rats were randomized, weighed, and anesthetized. Following feeding protocols, blood was taken from the posterior vena cava, and from the part of whole blood, serum was isolated and kept at -80°C, until further use. Moreover, rats fasted overnight were then euthanized by the exsanguination method (as mentioned in the CPCSEA guidelines) and colons were excised. Other small portions of the colon were fixed in formalin, frozen in optimal cutting temperature (OCT) medium, and stored in RNA later at -20°C for isolating RNA.

Therefore, to induce the intestinal barrier injury rat model, we assigned rats to the following groups: (a) the control group—rats fed with a pair-fed diet containing maltodextrin (substituted isocalorically); (b) the ethanol control group—rats fed with the ethanol-containing Lieber DeCarli liquid diet for 25 days to induce intestinal barrier dysfunction; (c) experimental group-1—rats fed with 75 mg/kg body weight Met along with the ethanol containing Lieber DeCarli liquid diet for 25 days; (d) experimental group-2—rats fed with  $10^8$  CFU/day Probiotic V along with the ethanol containing Lieber DeCarli liquid diet for 25 days; and (e) experimental group-3 with the combination—rats fed with 75 mg/kg body weight Met and  $10^8$  CFU/day Probiotic V along with the ethanol-containing Lieber DeCarli liquid diet for 25 days.



**2.6. Measurement of Transepithelial Electrical Resistance (TEER) in Caco-2 Monolayers.** To evaluate the intestinal barrier integrity, Caco-2 monolayers with a seeding density of  $1.0 \times 10^5$  cells/transwell were seeded in 12-well plates. The respective treatments given are based on the groups described earlier, and the percentage of TEER was measured. 0.5 ml and 1.5 ml media were added to the upper and lower chambers, respectively. The TEER value was measured by an epithelial volt ohmmeter. For blanks, inserts without cells were considered and their mean resistance was deducted from all control and treated samples. Triplicate measurements were recorded for each monolayer, and the average value was calculated to measure electrical resistance. TEER was calculated as follows:  $TEER = (R_m - \text{blank}) \times A$ ; where  $R_m$  = transmembrane resistance; blank = intrinsic resistance of a cell-free media; and  $A$  = membrane surface area ( $\text{cm}^2$ ) [27].

## 2.7. Determination of In Vitro and In Vivo Intestinal Permeability

**2.7.1. In Vitro Model.** To measure the intestinal epithelial barrier permeability, fluorescein isothiocyanate- (FITC-) dextran (FD-4), a paracellular marker, was chosen, and the amount of the marker that passes the Caco-2 cell monolayers was measured. Briefly, Caco-2 cells were seeded in 12-well plates at a density of  $1.0 \times 10^5$  cells/well for 21 days. The respective treatments given are based on the groups described earlier. Afterward, FD-4 was added to the apical compartment of the Caco-2 monolayer transwell inserts and incubated for 30 min. The FD-4 outflow into the lower basal compartment was measured at the excitation wavelength of 485 nm and an emission wavelength of 530 nm using a fluorescence spectrophotometer (Perkin Elmer LS-55, USA) [28].

**2.7.2. In Vivo Model.** After three hours from the last oral gavage, FD-4 dissolved in saline (500 mg/kg body weight, 125 mg/mL) was orally administered to rats. Later, animals were euthanized, and serum levels were checked for FD-4 concentration after 3 hr using a fluorescence spectrophotometer (Perkin Elmer LS-55, USA) at an excitation wavelength of 485 nm and an emission wavelength of 530 nm [29].

**2.8. Determination of Colonic Myeloperoxidase (MPO) Activity.** Colonic tissue was extracted according to Bradley et al. [30] using hexadecyltrimethylammonium bromide (HTAB). The extracted sample was mixed with o-dianizidine HCl and hydrogen peroxide ( $\text{H}_2\text{O}_2$ ), and absorbance was read spectrophotometrically at 460 nm. The sum of the MPO activity present in each sample/g tissue weight causes a change in spectrophotometric absorbance of 1/min at 460 nm [30].

**2.9. Measurement of Serum Endotoxin Concentration.** Serum endotoxin concentration levels were determined using the commercially available endotoxin quantitation kit (Thermo Fisher Scientific) following the kit manufacturer's guidelines. Endotoxin concentrations were expressed in endotoxin units/mL.

**2.10. Analysis of Colon Histology by H&E Staining.** Colon tissue sections fixed in formalin solution were processed in OCT medium. Five to 10  $\mu\text{M}$  colon sections were cut using a cryostat device. To distinguish the morphological changes among the differentially treated rats, paraffin-fixed colon sections were stained with hematoxylin-eosin (HE) solution. All the slide sections were observed by a single investigator who was blinded to the treatment status. All images captured represent at least five random areas per colon section per treatment group.

**2.11. Estimation of ROS Production.** The amount of ROS was measured following the method used by Heidari et al. in 2016 [31] with modification. Briefly, colon tissue was homogenized in 1:10  $w/v$  Tris-HCl buffer (pH 7.4, 40 mM). After homogenization, 100  $\mu\text{l}$  of colon homogenate was mixed with 1 ml of Tris-HCl buffer and incubated with 5  $\mu\text{l}$  of carboxy-H2-DCFDA [5(6)-carboxy-2',7'-dichlorofluorescein diacetate] in the dark with a final concentration of 10  $\mu\text{M}$  at 37°C for 1 hr. The samples' fluorescence intensity was measured at 485 nm excitation wavelength and 525 nm emission wavelength for measuring the total of ROS production using a fluorescence spectrophotometer (Perkin Elmer LS-55, USA) [31].

## 2.12. Estimation of Colonic Oxidative Stress

**2.12.1. Estimation of the Colonic MDA Content by TBA Method.** To make 10% homogenate, colon tissues were taken and processed with ice-cold potassium chloride (KCl) solution with the final concentration of 1.15% ( $w/v$ ). In the colon homogenate, concentrations of MDA were measured by the TBA method [32] using Cayman Chemical MDA estimation kit. The supernatant obtained was measured spectrophotometrically at the absorbance of 532 nm (UV-visible spectrophotometer model: PharmaSpec UV-1700, Shimadzu, Japan). For the calibration, each standard sample was repeated three times ( $n = 3$ ). A blank sample was repeated ( $n = 5$ ) replacing the standard or sample with a TCA-TBA-HCl reagent. Tissue protein levels were measured by the Lowry method, and the total MDA concentration obtained from each sample was then normalized to the protein concentration of the respective sample.

**2.12.2. Estimation of the Serum MDA Content by HPLC Method.** 500  $\mu\text{l}$  serum samples were mixed with 6 M sodium hydroxide (NaOH) (100  $\mu\text{l}$ ) and incubated at 60°C in a water bath for 45 min. The hydrolyzed samples were mixed with 35% perchloric acid (250  $\mu\text{l}$ ) for acidification and centrifuged for 10 min at  $15000 \times g$ . Later, supernatant (250  $\mu\text{l}$ ) was mixed with 2,4-dinitrophenylhydrazine (DNPH) (25  $\mu\text{l}$ ) solution and incubated in the dark for 10 min. The derivatized serum sample was then analyzed using HPLC apparatus (Waters Breeze-2, USA), through the ODS2 reverse-phase column. Acetonitrile and HPLC-grade water having 0.2% acetic acid at a ratio of 38:62 was used as mobile phase. HPLC was done under isocratic conditions with a flow rate of 1.0 ml/min, and MDA content in the samples was detected at 310 nm using a UV detector.

TABLE 1: The list of *Homo sapiens* primers used for the quantification of mRNA expression levels in qRT-PCR.

Sr. no.	Name of the gene	Forward primer sequence	Reverse primer sequence
1	18S	ACGGAAGGGCACCACCAGGA	CACCACCACCCACGGAATCG
2	ZO-1	TATTATGGCACATCAGCACG	TGGGCAAACAGACCAAGC
3	Occludin	CTCGAGAAAGTGCTGAGTGCCTGGAC	AAGCTTTCGGTGACCAATTCACCTGA
4	CYP2E1	AGGGTACCATGTCTGCCCTCGGAGTGA	ACAATTTGAAAGCTTGTTTGAAAGCGG
5	NOX	GTACAAATTCCAGTGTGCAGACCAC	GTACAAATTCCAGTGTGCAGACCAC
6	TNF- $\alpha$	CCCTCACACTCAGATCATCTTCT	GCTACGACGTGGGCTACAG
7	IL-6	GACAACTTTGGCATTGTGG	ATGCAGGGATGATGTTCTG
8	IL-10	ACTGCTAACCGACTCCTTA	TAAGGAGTCGGTTAGCAGT

(1) *Preparation of Standard Curve.* 20 nmol/ml of MDA standard stock solution was prepared from 1,1,3,3-tetraethoxypropane (TEP) (TCI, Japan), and further diluted with 1%  $\text{H}_2\text{SO}_4$  to yield a final concentration of 0.10, 0.20, 0.31, 0.62, 1.25, 2.50, 5.00, and 10.00 nM/ml of MDA. To 250  $\mu\text{l}$  of each standard sample, 25  $\mu\text{l}$  of DNPH was added and incubated for 10 min in the dark [33].

**2.12.3. Evaluation of Antioxidant Capacity.** The colon tissue was mechanically homogenized and centrifuged at  $3000 \times g$  for 15 min. The colon tissue weight to physiological saline ratio was 1:9 v/v. Glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and catalase (CAT) in the supernatant of homogenate were detected by using commercial assay kits (Thermo Fisher Scientific, USA).

**2.13. Estimation of Butyrate Levels in the Serum.** 20  $\mu\text{l}$  serum samples were mixed with 100  $\mu\text{l}$  methanol, followed by a vigorous vortex. Later, the mixture was centrifuged at  $4800 \times g$  for 10 min at  $4^\circ\text{C}$ , and further supernatant was collected and analyzed through the C18 chromatographic column. Acetonitrile and HPLC-grade water having 0.1% phosphoric acid solution at a ratio of 20:80 was used as a mobile phase. HPLC was done under isocratic conditions with a flow velocity of 1.0 ml/min, and butyrate levels in the sample were detected at 206 nm using a UV detector [34].

**2.13.1. Standard Curve Preparation.** We diluted 0.1 g butyrate standard solution with HPLC-grade water to 100 ml and filtered it through a 0.45  $\mu\text{m}$  Millipore filter. Standard solution was introduced at 0  $\mu\text{l}$ , 5  $\mu\text{l}$ , 10  $\mu\text{l}$ , 20  $\mu\text{l}$ , 30  $\mu\text{l}$ , and 50  $\mu\text{l}$ .

**2.14. Extraction of RNA and Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR).** Caco-2 monolayer cells were seeded in 6-well plates at the seeding density of  $2.0 \times 10^5$  cells/ml and cultured for 21 days. Afterward, probiotic V (10  $\mu\text{l}$ ), Met (1 mM), and ethanol (100 mM) were added according to their respective groups and incubated for 48 h. Cells were harvested using the TRIzol Reagent extraction method. Also, for *in vivo* studies, a total of 4 mg of colonic RNA was isolated from the colon tissue using the TRIzol Reagent extraction method. The concentrations (ng/ $\mu\text{l}$ ) and purity (A260/A280) of extracted RNA were measured by a NanoDrop instrument (Thermo Fisher Scientific, Waltham, MA, USA). Extracted

RNA was given a DNase treatment, and cDNA was synthesized from 1  $\mu\text{g}$  of total RNA using a first-strand cDNA synthesis kit, according to the manufacturer's protocol. Real-time PCR amplification for quantifying the gene expressions was done using the SYBR/ROX Master Mix in an Agilent Mx3005P qPCR system (Agilent Stratagene) for the following primers (Tables 1 and 2). The respective gene expressions were normalized to the 18S rRNA gene expression (endogenous control). The quantification of results was done using the  $2^{-\Delta\Delta\text{CT}}$  method [35] and expressed as fold-over basal change comparative to the control group.

**2.15. Statistical Analysis.** The values of the replicates were calculated as mean  $\pm$  SD. To evaluate the statistical data, GraphPad Prism 7 software using one-way analysis of variance (ANOVA) was used. Statistical variations among the different experimental sets of groups were considered to be significant at a  $p$  value less than 0.05.

## 2.16. In Silico Analysis

**2.16.1. Preparation of Proteins Using Homology Modeling.** Due to the unavailability of 3D structures for *Rattus norvegicus*, protein modeling of SLC5A8 and Nrf-2 was performed based on known crystal structures from the Protein Data Bank (PDB) [36] using homology modeling through the SWISS-MODEL server [37]. The amino acid FASTA sequence of these three proteins used to build the model was retrieved from UniProt [38] (Accession ID: D3Z9E5, O54968, and Q80Z39, respectively). Afterward, the model was generated based on the quality analysis of the predicted model as conducted and was evaluated on the basis of Qualitative Model Energy Analysis (QMEAN) [39] and Global Model Quality Estimation (GMQE) score. GMQE score ranges between zero and one, and the score for the modeled protein closer to 1 indicates increased structural reliability. Another parameter of QMEAN Z-scores closer to zero indicate good agreement between the model structure and experimental structures of similar size. Scores of -4.0 or below is an indication of models with low quality, highlighted by a change of the “thumbs-up” symbol to a “thumbs-down” symbol next to the score. Further, MolProbity 4.5.1 [40] was used to build the Ramachandran plot to analyze the psi and phi angles of the modeled proteins. Target-template alignment of sequences of the three

TABLE 2: The list of *Rattus norvegicus* primers used for the quantification of mRNA expression levels in qRT-PCR.

Sr. no.	Name of the gene	Forward primer sequence	Reverse primer sequence
1	18S	GTTGGTTTTCGGAAGTGAAGG	GTCGGCATCGTTTATGGTCG
2	ZO-1	TCGGAGCTCGGGCATTATTC	CAGGGCACCATAACCAACCAT
3	Occludin	CAACGGCAAAGTGAATGGCA	CTTTCCCTTCGTGGGAGTC
4	Nrf-2	CAGAGTTTCTTCGCCAGAGG	TGAGTGTGAGGACCCATCG
5	HO-1	CAAATCCCACCTGAACACA	CGACTGACTAATGGCAGCAG
6	CYP2E1	TCAATCTCT GGACCCCAACTG	GCGCTCTGCACTGTGCTTT
7	NOX	TGACAGTGATGTATGCAGCAT	CAGCTTGTGTGTGCACGCTG
8	CHOP	ACCACCACACCTGAAAGCA	AGCTGGACACTGTCTCAAAGG
9	Grp78	CCGTAACAATCAAGGTCTACGA	AAGGTGACTTCAATCTGGGGTA
10	TNF- $\alpha$	TCTCATTCTGCTCGTGGCG	GGTGAGGAGCACGTAGTCGG
11	IL-6	TTGACAGCCACTGCCTTCCC	CGGAACTCCAGAAGACCAGAGC
12	IL-10	TGCCTTCAGTCAAGTGAAGAC	AAACTCATTTCATGGCCTTGTA
13	AMPK	GCTGTGGATCGCCAAATTAT	GCATCAGCAGAGTGGCAATA
14	SREBP-1c	TCTGCCCTTGATGAAGTGTGG	AGCAGCCCCTAGAACAAACA
15	FASN	CCTCAGTCCTGTTATCACCCGA	GCTGAATACGACCACGCACTA
16	ACC	CCTTCTTCTACTGGCGACTGAG	TAAGCCTTCACTGTGCCTTCC
17	GPR109A	ACTTCTGGTGATAAACGCAAGA	GACTGTCAGCCGATGGTG
18	SLC5A8	AGCCAGCACTCAGCGTATTT	TTTGAGCTCCAATTCCAACC

proteins for their template protein sequences was aligned using ClustalW [41]. The crystal structures for *Rattus norvegicus* GPR109A were built using the Robetta server (<http://robeta.bakerlab.org>) [42], and the Ramachandran plot was built using PROCHECK [43] on SAVES server v6.0 (<https://saves.mbi.ucla.edu/>). The X-ray-diffracted 3D structure for *Rattus norvegicus* heme oxygenase (PDB ID: 6J7A) was available, and hence, directly retrieved from PDB.

**2.16.2. Molecular Docking.** *In silico* experiments were performed to study the protein-ligand interaction and binding affinity [44]. For performing protein-ligand interaction, four of the proteins were first optimized for docking studies one by one and were prepared by assigning the hydrogen atoms and charges followed by energy minimization using the DockPrep tool [45]. Partial charges are assigned as an atom attribute as per the AM1-BCC method to generate high-quality atomic charges for protein. Charges for nonstandard residues, if any, were calculated using Amber's Antechamber module [46]. The energy minimization was performed using the 10,000 steepest descent steps with 0.02 Å step size and an update interval of 10 for all four proteins individually. All the steps mentioned above were performed using UCSF Chimera 1.15 [47].

The 3D conformations for both butyrate (CID: 104775) and Met (CID: 4091) to perform docking were retrieved from PubChem [48]. This was followed by optimization of both ligands through the Gasteiger algorithm [49] in the structure editing wizard of UCSF Chimera 1.15, which works on the chemoinformatic principle of electronegativity equilibration; the ligand files were saved in mol2 format, as per the methodology adopted previously in a published work [50, 51].

Out of four, all the three proteins Nrf-2, GPR109A, and SLC5A8 were modeled for species *Rattus norvegicus* and lacked the predefined ligand-binding site. Hence, the ligand-binding site information and the amino acids involved in the protein-ligand interaction at the cleft were chosen based on the crystallized ligand attached in the original PDB file of the template protein that was used to build the respective *Rattus norvegicus* protein structure. For HO-1 (PDB ID: 6J7A), the native ligand was removed before docking, and the protein was treated similarly to the modeled proteins. As we want to look into the synergistic effect of butyrate and Met working in tandem, it becomes important to screen all other potential ligand-binding sites as well on these four respective proteins. This was achieved by performing molecular protein-ligand docking in three stages: (i) Blind or global docking which enables identifying the ligand-binding sites on multiple cavities in and on the structure of a particular protein; this strategy is particularly advantageous when the ligand-binding sites on the structure of the proteins are unknown, like in the case of this study. (ii) Single Ligand Localized docking (SLLD) which enables identifying the actual orientation of the ligand bound to a protein at the binding site. (iii) Multiple Ligand Simultaneous Docking (MLSD), as the name suggests, allows simultaneous interactions of multiple ligands at the active cleft of the protein. MLSD varies from SLLD by allowing different conformations of multiple ligands at random to run simultaneously. For running MLSD, the individual docking parameter files for each ligand, i.e., butyrate and Met, were merged as one, minimized again, and saved as an AutoDock ligand in pdbqt format.

Protein-ligand docking analysis was conducted using AutoDock Vina [52], and the program has executed an add-on in Chimera. Of all the possible poses suggested after




FIGURE 1: Effect of probiotic V and Met unaided or in combination on ethanol-induced gut dysbiosis. (a) Body weight. (b) Relative colon weight to length ratio. Values are expressed as mean  $\pm$  SD of six rats. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. <sup>#</sup> $p < 0.05$  and <sup>####</sup> $p < 0.0001$  compared to the control group; <sup>\*</sup> $p < 0.05$ , <sup>\*\*</sup> $p < 0.01$ , <sup>\*\*\*</sup> $p < 0.001$ , and <sup>\*\*\*\*</sup> $p < 0.0001$  compared with the ethanol-fed group; <sup>a</sup> $p < 0.05$  compared with the E + probiotic V group; <sup>b</sup> $p < 0.05$  compared with the E + Met group.

docking both the ligands with an individual protein, the pose showing maximum hydrogen bond-forming ability and minimum binding free energy change (kcal/mol) as observed in the ViewDock window were chosen as the best-docked pose. Best poses were then visualized in BIOVIA Discovery Studio [53] for hydrogen bond formation by the functional groups of ligands with amino acids as part of the protein. The visualizer also suggested other supporting hydrophobic interactions made by the ligands in the cavity of the protein.

### 3. Results

**3.1. Combinatorial Treatment of Probiotic V and Met Improves the Increased Colon Weight to Length Ratio in the Rat Model of Ethanol-Induced Intestinal Barrier Injury.** Figure 1 shows decreased body weight (BW) and increased colon weight/length ratio in the ethanol-fed group as compared to the control group. Interestingly, administration of probiotic V and Met in combination significantly increased the BW and decreased the colon weight/length ratios compared to the ethanol-fed groups and individual treatment of either probiotic V or Met. However, nonsignificant differences were observed in the case of BW when compared to the individual treatment of either probiotic V or Met.

**3.2. Combinatorial Treatment of Probiotic V and Met Improves Histological Modification in Colon Tissue.** Analysis of the HE-stained colon sections of control rats demonstrated the normal architecture of colon tissue with straight tubular glands lined by well-organized epithelial cells and lining as well as crypts of Lieberkühn. The vertically oriented crypts were lined by columnar epithelial cells. The ethanol-fed group showed disorganized epithelial cells, deformed crypts, and mucosal lining of colon. The surface area of crypts of Lieberkühn also showed remarkable reduction.

However, histological analysis of the ethanol-fed group treated with the combined administration of probiotic V and Met showed histology similar to the normal group (Figure 2).

**3.3. Combinatorial Treatment of Probiotic V and Met Attenuates Ethanol-Induced Disruption of TJ Expression and Intestinal Barrier Dysfunction.** TJs exert a crucial role in preventing gut integrity. Concerning the gene expression analysis of TJ proteins including ZO-1 and occludin, the transcriptions of both genes were significantly reduced in ethanol-exposed Caco-2 monolayers (Figures 3(c) and 3(d)) as well as the colon (Figures 4(b) and 4(c)). The expression of ZO-1 and occludin demonstrated an overall trend of upregulation after the individual treatment of probiotic V or Met, which was further more significantly upregulated by the two in the combinations.

In parallel, we also determined the combinatorial effect of probiotic V and Met on intestinal epithelial cell integrity *in vitro* and *in vivo*. *In vitro*, results showed that cells exposed to ethanol showed a significant decrease in TEER measurement indicating ethanol markedly disrupts the intestinal epithelial barrier. However, the decreased TEER induced by ethanol was significantly improved by the combined treatment of probiotic V and Met when compared with the ethanol-fed group as well as probiotic V- and Met-unaided groups (Figure 3(a)). Correspondingly, the cells incubated with ethanol greatly increased the FD-4 permeation over that in the control group, which was significantly attenuated by the combined treatment of probiotic V and Met in comparison to the ethanol group as well as either the probiotic V- or Met- ( $p < 0.05$ ) unaided groups (Figure 3(b)). In the *in vivo* model, mucosal permeability to FD-4 flux (Figure 4(a)) was higher in ethanol-fed rats compared to the control group. Ethanol feeding, however, failed to increase FD-4 flux permeability and endotoxins






FIGURE 2: Effect of probiotic V and Met unaided or in combination on histopathological modifications in inhibiting the ethanol-induced intestinal injury. (a) Gross examination of rat colon morphology (400x magnification). Microscopic images are as follows: (a) Control rats supplemented with maltodextrin (substituted isocalorically). (b) Ethanol-fed rats supplemented with increasing concentrations of ethanol. (c) Met: ethanol-fed rats supplemented with 75 mg/kg Met. (d) Probiotic V: ethanol-fed rats supplemented with probiotic V ( $10^8$  CFU/day). (e) Probiotic V and Met: ethanol-fed rats supplemented with a mixture of probiotic V ( $10^8$  CFU/day) and Met (75 mg/kg).

levels, when administered with probiotic V or Met individually. Moreover, combined administration of probiotic V and Met significantly decreased the FD-4 permeation compared to the individual treatment of probiotic V or Met. Taken together, the above results indicate that combined treatment of probiotic V and Met restored the damaged TJs, and intestinal barrier function caused by the ethanol in an *in-vitro* and *in-vivo* model of intestinal barrier injury.

**3.4. Combinatorial Treatment of Probiotic V and Met Attenuates Ethanol-Induced Intestinal Oxidative Stress.** To explore the combined effect of probiotic V and Met on intestinal oxidative stress, we investigated the ROS generation on rat colon tissues. We observed that the production of ROS was promoted manifestly by ethanol stimulation; meanwhile, either individual treatment of probiotic V or Met noticeably reduced the ROS accumulation, which was further dramatically diminished by the two in combination as compared to the ethanol group as well as individual treatment of probiotic V or Met (Figure 5(a)). Increased ROS production caused lipid peroxidation, thus resulting in malondialdehyde (MDA) generation.

Using HPLC, serum analysis of MDA levels showed higher MDA content in the ethanol-fed group ( $83.48 \pm 0.89$  nM/ml) compared to the control group ( $32.33 \pm 0.82$

nM/ml), indicating that severe oxidative stress occurred due to ethanol. On the other hand, in the group with combinatorial treatment of probiotic V and Met cotreated with ethanol, the MDA content decreased to normal levels ( $37.08 \pm 0.72$  nM/ml) compared to the ethanol-fed group as well as with either individual agent probiotic V ( $59.83 \pm 3.78$  nM/ml) or Met ( $67.40 \pm 1.94$  nM/ml). The colonic MDA content in the rats was measured by the TBA method. The MDA concentration in ethanol-fed rats was found to be  $1.07 \pm 0.06$   $\mu$ M/ml as compared to the control group ( $0.06 \pm 0.01$   $\mu$ M/ml). However, feeding the rats with probiotic V and Met in combination along with the ethanol showed reduced MDA levels to  $0.22 \pm 0.02$   $\mu$ M/ml compared with the ethanol-fed group as well as with either individual agent probiotic V ( $0.46 \pm 0.04$   $\mu$ M/ml) or Met ( $0.47 \pm 0.05$   $\mu$ M/ml) (Figures 5(b)–5(d)).

Under oxidative stress, transcription factor-like nuclear factor-like 2 (Nrf2) and enzyme-like heme-oxygenase (HO-1) plays a role in the regulation of antioxidant machinery. Ethanol feeding caused a graphic reduction in expression levels for the Nrf-2 and HO-1 genes in colonic mucosa. The combined administration of probiotic V and Met significantly increased the expression levels of Nrf-2 and HO-1 compared to the ethanol-fed groups as well as the probiotic V or Met-unaided groups (Figures 5(e) and 5(f)). The




FIGURE 3: Effect of probiotic V and Met unaided or in combination on ethanol-induced intestinal barrier integrity and permeability in Caco-2 monolayers. (a) TEER. (b) FD-4 influx. Gene expression levels of (c) ZO-1 and (d) occludin. Values are expressed as mean  $\pm$  SD of three individual experiments. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. # $p < 0.05$ , ## $p < 0.01$ , and #### $p < 0.0001$  compared to the control group; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and \*\*\*\* $p < 0.0001$  compared with the ethanol-fed group; <sup>a</sup> $p < 0.05$  and <sup>aa</sup> $p < 0.01$  compared with the E + probiotic V group; <sup>b</sup> $p < 0.05$  and <sup>bb</sup> $p < 0.01$  compared with the E + Met group.

treatment with either probiotic V or Met alone upregulated the activities of GSH-Px, SOD, and CAT which was further elevated by the combined treatment of probiotic V and Met of the ethanol-fed group as well as individual treatment of either probiotic V or Met (Figures 5(g)–5(i)).

Ethanol metabolism involving CYP2E1 enzyme and NADPH-oxidase (NOX) causes lipid peroxidation, and further, it forms protein adducts as a result of the end product of lipid peroxidation. This also affects the ER functioning and protein folding. *In vivo*, levels of ER stress markers like CHOP and Grp78 were significantly elevated in the ethanol-fed group as compared to control group (Figures 6(c) and 6(d)). Also, *in vitro* and *in vivo*, levels of CYP2E1 enzyme and NOX were significantly elevated in the ethanol group in comparison to the control group. The treatment with either probiotic V or Met alone downregulated the activities

of CYP2E1, NOX (Figures 6(a), 6(b), and 7), CHOP, and Grp78, which were further reduced by the combined treatment of probiotic V and Met of the ethanol-fed group as well as individual treatment of either probiotic V or Met. Our study demonstrated that probiotic V and Met in the presence of ethanol is effective in preventing the ethanol-induced oxidative stress along with ER stress in both cells and colon tissue of rat model of gut injury.

**3.5. Combinatorial Treatment of Probiotic V and Met Blocks Ethanol-Induced Intestinal Inflammation.** There is a strong piece of evidence demonstrating the link between intestinal barrier dysfunction and intestinal inflammation. Myeloperoxidase (MPO) is considered the hallmark of inflammation in the tissue. Also, endotoxin, i.e., serum LPS levels are known to be important to determine the translocation of




FIGURE 4: Effect of probiotic V and Met alone or in combination on ethanol-induced intestinal barrier integrity in the Wistar rat model. (a) Percentage of FD-4 permeation. (b) TJ protein expression of ZO-1 and (c) occludin. Values are expressed as mean  $\pm$  SD of six rats. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. ###  $p < 0.001$  and \*\*\*\*  $p < 0.0001$  compared to the control group; \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , and \*\*\*\*  $p < 0.0001$  compared with the ethanol-fed group; <sup>a</sup> $p < 0.05$ , <sup>aa</sup> $p < 0.01$ , and <sup>aaa</sup> $p < 0.001$  compared with the E + probiotic V group; <sup>b</sup> $p < 0.05$ , <sup>bb</sup> $p < 0.01$ , and <sup>bbb</sup> $p < 0.001$  compared with the E + Met group.

bacterial products and intestinal permeability. In the current study, we observed that colonic MPO activity and serum LPS levels were significantly upregulated in ethanol-fed rats compared to control rats. Ethanol-fed rat co-treated with either probiotic V or Met showed reduced colonic MPO activity (Figure 8(a)) and serum LPS levels (Figure 8(b)) compared to the ethanol groups, which were more significantly reduced by the combinatorial treatment of probiotic V and Met.

Similarly, by analyzing the gene expression by qRT-PCR, we found that the ethanol group showed an elevation in the expression levels of proinflammatory genes like TNF- $\alpha$  and IL-6, compared to the control group. Downregulation of anti-inflammatory expression levels of IL-10 was observed in the ethanol group. Treatment with either probiotic V or Met fundamentally switched all the expression levels, i.e., decreased expression levels of TNF- $\alpha$  and IL-6, as well as increased expression levels of IL-10, when compared with

the ethanol group, which was equally improved by the combinatorial treatment when compared with either individual treatment of probiotic V or Met (Figures 8(c)–8(e) and 9). The results suggest that combined treatment of probiotic V and Met can prevent ethanol-induced intestinal inflammation by regulating the levels of TNF- $\alpha$  and IL-6 in an *in vitro* and *in vivo* model of intestinal barrier injury.

**3.6. Combinatorial Treatment of Probiotic V and Met Regulates the Lipid Metabolism in the Colonic Mucosa of the Rat Model.** To determine the combined effect of probiotic V and Met in protecting the intestinal barrier, we determined the adenosine monophosphate-activated protein kinase (AMPK) levels. Indeed, chronic alcohol consumption leads to abnormal lipid metabolism in the colonic mucosa by decreased AMPK activation which leads to increased sterol regulatory element-binding protein 1c (SREBP-1c) (also a key regulator of lipid metabolism) expression, further




FIGURE 5: Continued.






FIGURE 5: Probiotic V and Met unaided or in combination prevent ethanol-mediated ROS production and oxidative stress in ethanol-induced intestinal injury. (a) Fluorescence spectroscopy with excitation/emission wavelengths at 485 nm/525 nm after incubation with carboxy-H<sub>2</sub>-DCFDA. (b) Total serum MDA levels. Here, the MDA levels in serum were quantified with reference to the standard area under the curve (AUC). (c) Total MDA concentration in colon tissue. The MDA content was quantified using the TBA assay method. (d) HPLC chromatograms of total serum MDA after DNPH derivatization in (a) standard, (b) control, (c) ethanol-fed, (d) Met (75 mg/kg) + ethanol-fed, (e) probiotic V ( $10^8$  CFU/day) + ethanol-fed, and (f) probiotic V ( $10^8$  CFU/day) + Met (75 mg/kg) + ethanol-fed rats. The amount of MDA present in serum was estimated after processing and DNPH derivatization. The serum sample after derivatization was then analyzed by a Shimadzu HPLC instrument using a fully end-capped spherical ODS2 C18 reverse-phase HPLC column. For the mobile phase, acetonitrile-distilled water with a ratio of 38:62 consisting of 0.2% glacial acetic acid was used. Colonic expression of antioxidants (e) Nrf-2, (f) HO-1, (g) GSH-Px, (h) SOD, and (i) CAT. The gene expression levels were measured after normalizing against 18S. Values are expressed as mean  $\pm$  SD of six rats. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. # $p$  < 0.05, ### $p$  < 0.001, and \*\*\*\* $p$  < 0.0001 compared to the control group; \* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001, and \*\*\*\* $p$  < 0.0001 compared with the ethanol-fed group; <sup>a</sup> $p$  < 0.05, <sup>aaa</sup> $p$  < 0.001, and <sup>aaaa</sup> $p$  < 0.0001 compared with the E + probiotic V group; <sup>b</sup> $p$  < 0.05, <sup>bb</sup> $p$  < 0.01, and <sup>bbb</sup> $p$  < 0.001 compared with the E + Met group.

remarkably increasing lipogenesis by activating the downstream lipogenic genes, i.e., acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) in ethanol-fed rats. Probiotic V or Met-unaided treatment upregulated the AMPK levels and lipid metabolism regulator, which is another way of being inhibited in the presence of ethanol. AMPK activation inhibits the expression of transcription factor, i.e., SREBP-1c, thereby preventing ethanol-induced lipogenesis. Consistent with the changed expression of SREBP-1c, the combination of probiotic V and Met also showed reduced expression

levels of ACC and FAS as compared to the ethanol group, which was remarkably reduced as compared to individual treatment of probiotic V or Met (Figures 10(a)–10(d)).

Also, colonic contents of total cholesterol (TC) and triglyceride (TG) in the ethanol-fed rats, were significantly upregulated compared to those in the control group, which were significantly reduced in the combinatorial treatment of probiotic V and Met in comparison to the ethanol-fed group as well as the probiotic V or Met-unaided group (Figures 10(e) and 10(f)). The above results depicted that




FIGURE 6: Probiotic V and Met alone or in combination prevents ethanol-mediated oxidative stress and endoplasmic reticulum (ER) stress in the male Wistar rat model. mRNA expression of (a) CYP2E1, (b) NOX and ER stress gene (c) CHOP, and (d) Grp78 in the male Wistar rat colon. The gene expression levels were measured after normalizing against 18S. Values are expressed as mean  $\pm$  SD of six rats. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. ### $p$  < 0.001 and #### $p$  < 0.0001 compared to the control group; \* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001, and \*\*\*\* $p$  < 0.0001 compared with the ethanol-fed group; <sup>a</sup> $p$  < 0.05, <sup>aa</sup> $p$  < 0.01, and <sup>aaa</sup> $p$  < 0.001 compared with the E + probiotic V group; <sup>b</sup> $p$  < 0.05, <sup>bb</sup> $p$  < 0.01, and <sup>bbb</sup> $p$  < 0.001 compared with the E + Met group.

the combined treatment of probiotic V and Met could restore the colonic metabolic function damaged by ethanol.

**3.7. Combinatorial Treatment of Probiotic V and Met Ameliorates the Butyrate Sensing against Ethanol Exposure.** The recent review literature provides the piece of evidence depicting increased levels of butyrate in the mice treated with probiotic VSL#3. The individual, as well as combinatorial treatment of probiotic V and Met, showed increased butyrate abundance in the *in vivo* model of ethanol-induced intestinal injury (Figure 11(a)). Taken together, also the expression of the butyrate receptor, i.e., GPR109A, and the butyrate transporter, i.e., SLC5A8, were reduced in the colon following the ethanol administration compared to the control group. In contrast, rats cotreated with either probiotic V or Met showed upregulated expression levels of GPR109A and SLC5A8 compared to the ethanol group (Figures 11(b) and 11(c)). Moreover, combined treatment of probiotic V and Met further improved more significantly,

proving the prevention of intestinal barrier injury-induced inflammation.

**3.8. Homology Modeling.** The 3D model structures of *Rattus norvegicus* Nrf-2, GPR109A, and SLC5A8 were built using SWISS-MODEL based on their FASTA sequences. The model for *Rattus norvegicus* Nrf-2 protein was built using template protein PDB ID: 2DYH, X-ray diffraction "Structure of apelin receptor in complex with agonist peptide" of *Homo sapiens* with a resolution of 2.60 Å. This template was chosen as the best available template to build the 3D structure for *Rattus norvegicus* Nrf-2 considering the 22.57% sequence identity, 0.46 GMQE score generated by the target-template alignment of the modeled protein, and QMEAN score of -4.86. Molpro results of the Ramachandran plot indicated 96.64% favored residues with only 0.34% amino acid residues marked as outliers, suggesting a satisfactory model (Supplementary Figures 1 and 2). For *Rattus norvegicus* GPR109A protein, template protein was built using the Robetta server and the results of




FIGURE 7: Probiotic V and Met alone or in combination prevents ethanol-mediated oxidative stress in Caco-2 monolayer cells. mRNA expression of (a) CYP2E1 and (b) NOX. The gene expression levels were measured after normalizing against 18S. Values are expressed as mean  $\pm$  SD of three individual experiments. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. ### $p$  < 0.001 and #### $p$  < 0.0001 compared to the control group. \*\* $p$  < 0.01, \*\*\* $p$  < 0.001, and \*\*\*\* $p$  < 0.0001 compared with the ethanol-fed group; <sup>a</sup> $p$  < 0.05 and <sup>aa</sup> $p$  < 0.01 compared with the E + probiotic V group; <sup>b</sup> $p$  < 0.05 and <sup>bb</sup> $p$  < 0.01 compared with the E + Met group.

Ramachandran plot were obtained using PROCHECK which indicated 92.3% favored residues with only 7.7% residues in a generously allowed region and 0.0% residues in disallowed regions (Supplementary Figures 3, 4, and 5). All these markers help us to predict that the proposed models are ideal modeled proteins for docking. Similarly, the model for *Rattus norvegicus* SLC5A8 was built using template protein PDB ID: 5NVA, an X-ray diffraction structure of "Substrate-bound outward-open state of a Na<sup>+</sup>-coupled sialic acid symporter reveals a novel Na<sup>+</sup>-site" of organism *Proteus mirabilis* HI4320 with a resolution of 2.26 Å. This template was chosen as the best available template to build the 3D structure for *Rattus norvegicus* SLC5A8 considering the 25.28% sequence identity, 0.52 GMQE score generated by the target-template alignment of the modeled protein, and QMEAN score of -5.94. The results for sequence identity and QMEAN Z-score indicate a low model quality. However, the Molprobit results of the Ramachandran plot indicated 95.97% favored residues with only 1.57% amino acid residues marked as outliers (Supplementary Figures 6, 7, and 8). Therefore, this proposed model was considered as an ideal modeled protein for *Rattus norvegicus* SLC5A8 and was chosen for molecular docking.

**3.9. Molecular Docking.** The coordinates of the ligand-binding site on four of the proteins were determined using blind/global docking. With no prior ligand interaction profile, grid maps were prepared by fixing the grid box on the entire structure of the protein. Optimal pose within conformation of the target protein-ligand-binding sites were noted for both Met and butyrate on each of the proteins. It is to be noted that blind docking is more demanding in terms of computational time and the results are less accurate but help to predict the affinity of the ligand candidates in their optimal pose within the target protein. The single ligand localized docking strategy was then implemented to identify the

exact orientation of the ligand on the protein and to validate the accuracy of the optimized pose in the identified binding cleft. As seen in Table 3, the Robetta-modeled Nrf-2 interaction with Met had a binding affinity of -6.0 kcal/mol, involving residues ILE: 559, VAL: 606, GLY: 367, GLY: 418, VAL: 512, and VAL: 465; with butyrate, it had a binding affinity of -3.4 kcal/mol, involving residues GLY: 605, ILE: 559, GLY: 367, and VAL: 606 (Figures 12(a) and 12(b)). HO-1 interaction with Met had a binding affinity of -5.7 kcal/mol, involving residues TYR: 286, ILE: 419, SER: 418, GLU: 565, HIS: 620, and GLU: 623; with butyrate, it had a binding affinity of -4.7 kcal/mol, involving residues ALA: 272, SER: 267, GLN: 268, TYR: 321, and THR: 269 (Figures 13(a) and 13(b)). The modeled GPR109A interaction with Met had a binding affinity of -4.9 kcal/mol, involving residues ASN: 321, ASN: 320, ARG: 308, SER: 323, THR: 324, and ARG: 311; with butyrate, it had a binding affinity of -3.4 kcal/mol, involving residues ILE: 162, ALA: 142, ASN: 65, PHE: 64, TRP: 56 (Figures 14(a) and 14(b)). Lastly, modeled SLC5A8 interaction with metformin had a binding affinity of -5.1 kcal/mol, involving residues GLN: 249, PHE: 458, and GLY: 462; with butyrate, it had a binding affinity of -4.7 kcal/mol, involving residues GLN: 82, and THR: 63 (Figures 15(a) and 15(b)). The results for MLSD reveal that Nrf-2 interaction with Met and butyrate had a simultaneous binding affinity of -9.7 kcal/mol, involving residues ASN: 321, VAL: 463, VAL: 604, LEU: 365, and LEU: 557 with Met, and ILE: 559, GLY: 367, and GLY: 558 with butyrate (Figure 12(c)). HO-1 interaction with Met and butyrate had a simultaneous binding affinity of -8.9 kcal/mol, involving residues GLU: 402, GLU: 623, LEU: 624, and LEU: 625 with Met, and PHE: 699, THR: 188, THR: 703, LYS: 700, and HIS: 803 with butyrate (Figure 13(c)). GPR109A interaction with Met and butyrate had a simultaneous binding affinity of -9.7 kcal/mol, involving residues ASN: 321, ASN: 320, ARG: 308, SER: 323, THR: 324, and ARG: 311 with




FIGURE 8: Probiotic V and Met alone or in combination inhibits ethanol-induced intestinal inflammation in the male Wistar rat model. (a) Effect on the myeloperoxidase activities in the colon. (b) Effect on the LPS levels in the blood. The inflammatory gene levels in the male Wistar rat colon of (c) TNF- $\alpha$  and (d) IL-6 and anti-inflammatory gene level of (e) IL-10. The gene expression levels were measured after normalizing against 18S. Values are expressed as mean  $\pm$  SD of six rats. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. # $p < 0.05$ , #### $p < 0.0001$  compared to the control group; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and \*\*\*\* $p < 0.0001$  compared with the ethanol-fed group; <sup>a</sup> $p < 0.05$  and <sup>aaa</sup> $p < 0.001$  compared with the E + probiotic V group; <sup>b</sup> $p < 0.05$ , <sup>bb</sup> $p < 0.01$ , and <sup>bbb</sup> $p < 0.001$  compared with the E + Met group.

Met, and ILE: 162, ALA: 142, ASN: 65, PHE: 64, and TRP: 56 with butyrate (Figure 14(c)). SLC5A8 interaction with Met and butyrate had a simultaneous binding affinity of -8.3 kcal/mol, involving residues GLN: 249, GLY: 412, and GLY: 242 with metformin, and GLN: 82, THR: 63, and VAL: 281 with butyrate (Figure 15(c)). Docking conformations were evaluated using these precalculated grid maps to enhance the robustness of docking. Binding energies and amino acid interaction for both the ligands are described in Table 3. There were several hydrophobic interactions such as alkyl and pi-alkyl bond formation occurring in the hydrophobic active site that is described in Figures 16, 17, 18, and 19.

#### 4. Discussion

The effect of alcohol at the pathophysiological level contributes to a leaky gut or dysbiosis leading to intestinal hyperpermeability of intestinal bacteria [7, 8, 54]. Understanding the pathophysiological mechanism behind the ethanol-induced intestinal barrier dysfunction, as the present study executed, is considered to be significant with regard to biological and clinical manifestation because disruption of intestinal barrier integrity, called a leaky gut syndrome, is reflected to be one of the chief mechanisms involved in alcohol-mediated endotoxemia in the progression of ALD. Despite extensive research over the past decade, the




FIGURE 9: Probiotic V and Met alone or in combination inhibits ethanol-induced intestinal inflammation in the Caco-2 monolayers. Inflammatory gene levels of (a) TNF- $\alpha$  and (b) IL-6 and anti-inflammatory gene level of (c) IL-10. The gene expression levels were measured after normalizing against 18S. Values are expressed as mean  $\pm$  SD of three individual experiments. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. <sup>###</sup> $p < 0.001$  compared to the control group; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and \*\*\*\* $p < 0.0001$  compared with the ethanol-fed group; <sup>a</sup> $p < 0.05$  compared with the E + probiotic V group; <sup>b</sup> $p < 0.05$  and <sup>bb</sup> $p < 0.01$  compared with the E + Met group.

molecular mechanisms for ethanol-induced intestinal barrier integrity dysfunction have remained unsuccessfully understood. During acute or chronic alcohol consumption, colon tissue has consistently been targeted.

At present, there are no available FDA-approved treatments to halt or cure alcoholic liver injury. Abstinence from drinking alcohol is known to be the only way to limit ALD development and progression. At this time, available treatments are single, and the ameliorative effect is not ideal [55]. One such individual known therapy is probiotics which protect against alcohol-induced gut leakiness [20]. For the first time, the current study proved the protective effect of Met against alcohol-induced gut leakiness. However, combined treatment of effective therapies can provide different links and targets to treat or prevent ethanol-induced gut dysbiosis through modulating intestinal mucosal barrier integrity, intestinal epithelial permeability, gut oxidation, and inflammatory response. Therefore, the current study cogitated that probiotic V in combination with Met could remarkably prevent the development of ethanol-induced intestinal barrier injury.

Recent studies demonstrated that chronic alcohol drinking leads to intestinal barrier dysfunction, increased intestinal permeability, and endotoxemia, which are considered to be initial events of ALD progression [56, 57]. The entire permeability of colon and Caco-2 monolayers were measured in the current study investigating the potential protective effect of combined treatment of probiotic V and Met on alcohol-induced intestinal mucosal barrier injury in both *in vitro* and *in vivo* models. Our results are following numerous studies, where Caco-2 monolayers and rat colonic epi-

thelium presented decreased TEER (%) and increased colonic mucosal permeability to FITC-inulin was observed in the ethanol group, which indicates that ethanol can induce substantial damage to the colon as seen in both *in vitro* and *in vivo* models [58, 59]. Studies reported that administration of probiotic VSL#3 decreased the ethanol-induced epithelial permeability [60]. Also, supplementation of *L. plantarum* improves the colonic mucosal barrier dysfunction induced by the ethanol-fed diet [20]. The report showed reduced TEER and FITC-dextran hyperpermeability with Met treatment in a dextran sodium sulfate- (DSS-) induced colitis model [24]. In accordance with the above results, our results also demonstrated that coadministration of probiotic V and Met significantly prevented the decreased levels of TEER and intestinal hyperpermeability induced by ethanol indicating the combinatorial treatment completely blocks the ethanol-induced intestinal barrier dysfunction.

Several studies reported that alcohol and/or its metabolite (i.e., acetaldehyde) causes intestinal mucosal barrier dysfunction through alterations in TJ proteins [61, 62]. The interplay between ZO-1 and occludin is crucial for the assembly and preservation of TJs as well as the development of mucosal barrier function [63]. Occludin is the first identified and integral membrane TJ protein, which plays an important role in maintaining the barrier function and structural integrity of TJs [64]. Also, ZO-1 is a cytoskeletal linker protein that forms cross-links with other transmembrane proteins like occludins, necessary for the connection of other TJ proteins to the cytoskeleton [65]. The report demonstrated that the administration of 40 mM ethanol to Caco-2 monolayers disrupted the TJs, specifically occludins




FIGURE 10: Probiotic V and Met unaided or in combination regulate the lipid accumulation in the colon to prevent ethanol-induced intestinal injury. mRNA expression of lipogenic genes (a) AMPK, (b) SREBP-1c, (c) FAS, and (d) ACC involved in lipid metabolism in the rat colon and (e) levels of TC and (f) TG in the colon. The gene expression levels were measured after normalizing against 18S. Values are expressed as mean  $\pm$  SD of six rats. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. ### $p$  < 0.001 and #### $p$  < 0.0001 compared to the control group; \* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001, and \*\*\*\* $p$  < 0.0001 compared with the ethanol-fed group; <sup>a</sup> $p$  < 0.05 and <sup>aa</sup> $p$  < 0.01 compared with the E + probiotic V group; <sup>b</sup> $p$  < 0.05, <sup>bb</sup> $p$  < 0.01, and <sup>bbb</sup> $p$  < 0.001 compared with the E + Met group.






FIGURE 11: Probiotic V and Met unaided or in combination in enhancing the expression of butyrate receptor and transporter proteins in a rat model of ethanol-induced intestinal injury. Expression levels of (a) serum butyrate levels; (b) butyrate receptor: GPR109A; and (c) butyrate transporter: SLC5A8. The gene expression levels were measured after normalizing against 18S. Values are expressed as mean  $\pm$  SD of six rats. Statistical analysis: one-way ANOVA followed by Tukey's post hoc test. ### $p$  < 0.001 and \*\*\*\* $p$  < 0.0001 compared to the control group; \*\* $p$  < 0.01, \*\*\* $p$  < 0.001, and \*\*\*\* $p$  < 0.0001 compared with the ethanol-fed group; <sup>a</sup> $p$  < 0.05, <sup>aa</sup> $p$  < 0.01, and <sup>aaa</sup> $p$  < 0.001 compared with the E + probiotic V group; <sup>b</sup> $p$  < 0.05 and <sup>bbb</sup> $p$  < 0.001 compared with the E + Met group.

TABLE 3: Binding energies and amino acid interaction for Met and butyrate on performing molecular docking with respective protein structures.

Protein	Ligand	Binding energy (kcal/mol)	Amino acid interactions
Nrf-2	SLLD Met	-6.0	ILE: 559, VAL: 606, GLY: 367, GLY: 418, VAL: 512, VAL: 465
	SLLD butyrate	-3.4	GLY: 605, ILE: 559, GLY: 367, VAL: 606
	MLSD Met and butyrate	-9.7	ILE: 559, GLY: 367, GLY: 558, VAL: 463, VAL: 604, LEU: 365, LEU: 557
HO-1	SLLD Met	-5.7	TYR: 286, ILE: 419, SER: 418, GLU: 565, HIS: 620, GLU: 623
	SLLD butyrate	-4.7	ALA: 272, SER: 267, GLN: 268, TYR: 321, THR: 269
	MLSD Met and butyrate	-8.9	PHE: 699, THR: 188, THR: 703, LYS: 700, HIS: 803, GLU: 402, GLU: 623, LEU: 624, LEU: 625
GPR109A	SLLD Met	-4.9	ASN: 321, ASN: 320, ARG: 308, SER: 323, THR: 324, ARG: 311
	SLLD butyrate	-3.4	ILE: 162, ALA: 142, ASN: 65, PHE: 64, TRP: 56
	MLSD Met and butyrate	-9.7	ILE: 162, ALA: 142, ASN: 65, PHE: 64, TRP: 56, ASN: 321, ASN: 320, ARG: 308, SER: 323, THR: 324, ARG: 311
SLC5A8	SLLD Met	-5.1	GLN: 249, PHE: 458, GLY: 462
	SLLD butyrate	-4.7	GLN: 82, THR: 63
	MLSD Met and butyrate	-8.3	GLN: 82, THR: 63, VAL: 281, GLN: 249, GLY: 412, GLY: 242

and ZO-1 [66]. Also, acute alcohol exposure disrupts the barrier function by downregulating the expressions of ZO-1 and occludin in colons of mice [18].

Supplementation of probiotic *L. plantarum* prevents the redistribution of TJ proteins (ZO-1 and occludin) from the colonic epithelial junction, which was induced by ethanol [20]. *A. muciniphila* showed protection against ethanol-induced gut leakiness by enhancing mucus thickness and TJ protein expression [67]. A scaffolding protein like tight

junction protein-1 (TJP-1) is a gene that encodes for ZO-1 protein, an essential protein required for the maintenance of epithelial barrier integrity. The report proved that TJP-1 gene overexpression may be considered as an index of elevated intestinal barrier integrity in a VSL#3-induced NOD mice model [68]. Studies showed that pretreatment of *L. plantarum* ZLP001 markedly prevented the decreases in ZO-1 and occludin mRNA expression levels which is caused by enterotoxigenic *Escherichia coli* (ETEC) infection [69]. In




FIGURE 12: Molecular 3D interaction of *Rattus norvegicus* Nrf-2 (modeled using PDB ID: 2DYH) with (a) Met, (b) butyrate performed through SLLD, and (c) Met and butyrate together performed through MLSD.






FIGURE 13: Molecular 3D interaction of *Rattus norvegicus* HO-1 (modeled using PDB ID: 6J7A) with (a) Met, (b) butyrate performed through SLLD, and (c) Met and butyrate together performed through MLSD.

both, Caco-2 monolayers and colitis mice model, Met administration provided protection against the decreased expression of occludin and ZO-1 as well as increased bacte-

rial translocation [24, 70]. In Caco-2 monolayers, Met ameliorates the inhibiting effect of TNF- $\alpha$  on epithelial tight junction-related protein expression [71]. Therefore, the




FIGURE 14: Molecular 3D interaction of *Rattus norvegicus* GPR109A (modeled using PDB ID: 5VBL) with (a) Met, (b) butyrate performed through SLLD, and (c) Met and butyrate together performed through MLSD.

current study depicted that coadministration of probiotic V and Met ameliorates the dislocation of TJ proteins induced by alcohol in an *in vitro* and *in vivo* model of ethanol-induced intestinal barrier injury.

Alcohol metabolism through CYP2E1 may be a contributing factor towards the ethanol-induced intestinal effects. It is proven that alcohol products mediated through CYP2E1 could be the main inducers towards the ethanol-induced




FIGURE 15: Molecular 3D interaction of *Rattus norvegicus* SLC5A8 (modeled using PDB ID: 5NVA) with (a) Met, (b) butyrate performed through SLLD, and (c) Met and butyrate together performed through MLSD.

gut barrier dysfunction and hepatic injury. CYP2E1-mediated alcohol metabolism causes increased oxidative stress products like MDA that can generate reactive oxygen

species/reactive nitrogen species (ROS/RNS) that can result in intestinal epithelial hyperpermeability or disruption [12, 13, 72]. A recent study showed increased CYP2E1 expression






FIGURE 16: Molecular 2D interaction of *Rattus norvegicus* Nrf-2 (modeled using PDB ID: 2DYH) with (a) Met, (b) butyrate performed through SLLD, and (c) Met and butyrate together performed through MLSD.

and activity in alcohol-induced Caco-2 monolayers and rodent models with gut leakiness [12]. Moreover, along with CYP2E1, there is also an activation of intestinal iNOS (also known as ROS-generating enzyme), which mediates ROS generation and, subsequently, mucosal barrier dysfunction induced by alcohol [73]. A recent study showed that individual as well as combined treatment of Met and probiotics significantly reduced ROS production in colorectal cancerous animals [74]. Reports showed that probiotics LC27 and LC67 may alleviate the GI inflammation by scavenging ROS [75]. Studies showed that Met treatment ameliorated the LPS-induced intestinal ROS production and oxidative stress [25]. Reports on Met showed decreased levels of TBARS and increased levels of antioxidant markers (GSH, SOD, and CAT) in colon tissue of the colitic rat model [76]. Current results depicting increased expression levels of CYP2E1 and iNOS along with colonic MDA resulted in the generation of ROS, which further resulted in alcohol-induced oxidative stress in rat colon. One result indicated a key finding of this study, i.e., combinatorial treatment of probiotic V and Met remarkably inhibit CYP2E1, thereby alleviating intestinal ROS generation and oxidative stress induced by alcohol.

To prevent oxidative stress, CYP2E1 also stimulates the expression of antioxidant factors like Nrf-2, which is considered to be one of the key transcription factors providing protection against oxidative stress/nitrative stress [77]. The transcription factor Nrf-2 is known to play an important

role in the regulation of antioxidant gene expression [78]. In colonic mucosa, ethanol induced a decrease in the expression levels of IL-10 [63]. The corresponding changes in the expression of a few antioxidant genes by alcohol may be mediated by Nrf-2. Nrf-2 is a known regulator for the expression of genes like Gpx and NQO1. It is unknown whether catalase and SOD genes are regulated by Nrf-2 [63]. Studies demonstrated that probiotic *L. plantarum* inhibits ethanol-induced oxidative stress by upregulating the Nrf-2 expression [20]. Also, a recent study showed that Met significantly enhanced the nuclear translocation of Nrf-2 and its related target genes like HO-1 induced by LPS treatment [25]. In the colorectal cancer model, mixtures of genetically modified *lactobacilli* strains showed the curative anticancer effect through a combination of various anti-inflammatory machinery and IL-10 stimulation [79]. Interestingly, the present study conferred increased antioxidant activity of GSH-Px, SOD, CAT, Nrf-2, and HO-1 in the rats treated with probiotic V and Met in combination in the presence of ethanol when compared with either individual treatment of probiotic V or Met.

To further validate and understand the role of probiotic V and Met, we performed in silico analysis to check if the cotreatment of Met and probiotic V could act in synergism to prevent intestinal barrier injury. We explored the role of Met and butyrate in the activation of antioxidants like HO-1 and Nrf-2. As hepatic fibrosis in ALD has been shown to




FIGURE 17: Molecular 2D interaction of *Rattus norvegicus* HO-1 (modeled using PDB ID: 6J7A) with (a) Met, (b) butyrate performed through SLLD, and (c) Met and butyrate together performed through MLSD.

be mitigated by antioxidants like Nrf-2 and HO-1, their inducers can be promising agents to prevent fibrosis in the liver. Therefore, we checked if probiotic V and Met could synergistically induce the expression of Nrf-2 and HO-1. Upon analysis of their interactions in being able to induce Nrf-2 and HO-1, we found that both probiotic V and Met individually showed interactions with Nrf-2 and HO-1, with binding energies (Nrf-2: -6.0 and -3.4 kcal/mol; HO-1: -5.7 and -4.7 kcal/mol), which was significantly improved when docked in combination (Nrf-2: -9.7 kcal/mol; HO-1: -8.9 kcal/mol). This suggests that both probiotic V and Met could much better induce the expression of Nrf-2 and HO-1 when administered together as compared to their individual treatment. The *in silico* results are in agreement with the *in vitro* and *in vivo* results where the combination of Met and probiotic V induced the expression of Nrf-2 and HO-1.

ALD has been shown to alter lipid metabolism and increase the levels of serum triglycerides. Reports suggest that high circulating triglycerides also render men with a twofold risk of developing colorectal cancer [80]. Various reports also suggest that dyslipidemia can be associated with developing colorectal carcinoma [81]. Similarly, the present study also showed remarkably elevated levels of colonic TGs and cholesterol in the ethanol-fed rats, which was improved by treatment with probiotic V and Met cotreatment. Our previous study showed that combinatorial treatment of probiotic V and Met is known to prevent lipogenesis in ALD in the liver [26]; therefore, we explored its role in inhibiting alcohol-induced lipogenesis by regulating specific lipid metabolism-associated transcription factors in the intestine. In the hepatic tissue, unaided administration of Met and probiotic V showed AMPK activation, which is otherwise inhibited in the presence of ethanol confirming






FIGURE 18: Molecular 2D interaction of *Rattus norvegicus* GPR109A (modeled using PDB ID: 5VBL) with (a) Met, (b) butyrate performed through SLLD, and (c) Met and butyrate together performed through MLSD.

its therapeutic role in lipid metabolism [26]. The current study depicted that coadministration of probiotic V and Met activates AMPK and meanwhile inhibits the expression of SREBP-1c, thereby ameliorating ethanol-induced lipogenesis. With the alteration in expression of SREBP-1c, it further deactivated the downstream signaling cascades, viz., lipogenic enzymes like ACC and FAS, overall improving the ethanol-induced intestinal barrier injury.

As discussed, ethanol metabolism involving CYP2E1 causes lipid peroxidation, and further, it forms protein adducts as a result of the end product of lipid peroxidation. This also affects the ER functioning and protein folding. In the ER, there is an accumulation of protein adducts which causes ER fragmentation [82]. The resulting misfolded proteins lead to the upregulated mRNA expression levels of ER stress-related transcription factor-like CHOP and protein-like Grp78 in alcohol-fed mice. In colonic tissues, studies reported improved ER stress which was relatively

responsible for the improved inflammation in colitis-infected mice [83]. Also, ethanol consumption upregulated the levels of CHOP and Grp78 in Caco-2 colon cancer cells [84]. No reports have depicted the role of Met in attenuating ER stress in colonic mucosa. Therefore, our report was the first one to depict the role of Met alone as well as in combination with probiotic V in attenuating the ethanol-induced ER stress in colonic mucosa. The present study also showed that probiotic V and Met in combination is capable of reducing the expression levels of ER stress genes (CHOP and Grp78) more significantly in the presence of ethanol when compared with the individual treatment of probiotic V or Met.

In the past decade, breakthrough inflammation research reported that intestinal inflammation and oxidative stress can cause a leaky gut barrier or hyperpermeability in the intestinal tract. In addition, a transgenic model with a leaky gut showed manifestation of intestinal inflammation [85].




FIGURE 19: Molecular 2D interaction of *Rattus norvegicus* SLC5A8 (modeled using PDB ID: 5NVA) with (a) Met, (b) butyrate performed through SLLD, and (c) Met and butyrate together performed through MLSD.

Intestinal inflammation is mostly connected with mucosal barrier dysfunction and TJ disruption [25]. It is known that alcohol-induced oxidative stress caused mucosal barrier dysfunction and epithelial TJ disruption, which resulted in luminal LPS leakage in the colonic mucosa. Ingestion of alcohol upregulates the myeloperoxidase activity in the colon [75]. Recent reports demonstrated the synergistic effect of Met and probiotic in reducing the levels of TNF- $\alpha$  and IL-6 in the colon and serum resulting in a marked improvement in the inflammatory response [74]. Studies showed that probiotic *L. plantarum* downregulated the expression levels of cytokines (TNF- $\alpha$ , IL-6, and IL- $\beta$ ) in the colonic mucosa, thereby preventing the ethanol-induced inflammatory response [20]. The study demonstrated that VSL#3 administration induces a remarkable

reduction in cytokine expression, i.e., IL-1 $\beta$  in the intestinal mucosa of the NOD mice [68]. The report showed that Met treatment could suggestively prevent LPS-induced proinflammatory cytokines like IL-6 and TNF- $\alpha$  expression in the mice model of intestinal tissue [25]. In agreement with the above reports, the present study also demonstrated the significantly increased mRNA expression levels of TNF- $\alpha$ , IL-6, and IL- $\beta$  in the ethanol group compared to the control in an *in vivo* and *in vitro* model. The present study demonstrated the downregulated expression of TNF- $\alpha$ , IL-6, and IL- $\beta$  indicating the anti-inflammatory effect of combinatorial treatment of probiotic V and Met in the *in vitro* as well as *in vivo* model.

It has been reported that a consortium of eight bacterial strains, i.e., VSL#3 (similar to Visbiome®), was shown to




FIGURE 20: Potential preventive mechanism of probiotic V and Met in combination against ethanol-induced intestinal barrier injury.

increase the levels of SCFA butyrate with no changes in other SCFAs [86]. Butyrate is considered to be a prime energy source for colonocytes and also helps in regulating intestinal homeostasis through anti-inflammatory mechanisms. In accordance with the above studies, the current study demonstrated the increased levels of butyrate in ethanol-fed rats treated with probiotic V. Therefore, it is of prime importance to understand how butyrate has been absorbed and transported to the intestine. Several studies showed that the butyrate receptor, i.e., GPR109A, and the butyrate transporter, i.e., SLC5A8, are required for the same, and their expressions are circumscribed to the apical membranes of intestinal and colonic epithelial cells [87, 88], thus permitting uninterrupted access to butyrate in the lumen. SLC5A8 is a butyrate transporter linked with  $\text{Na}^+$  required for the butyrate transport into cells [89]. GPR109A is a butyrate receptor that is intricately involved in the stimulation of surface expression and activity of butyrate transporters. These synchronized regulatory mechanisms eventually led to increased absorption of butyrate when elevated concentrations of butyrate are accessible [90]. Alcohol consumption as discussed earlier disrupts intestinal permeability by reducing the expression of TJ proteins. The restoration of intestinal permeability can be of higher therapeutic benefit to prevent the progression of ALD. The SCFA butyrate has been shown to promote the epithelial barrier function by upregulating the expression of genes encoding TJ constituents and protein reassembly through

STAT3 and SP1 activation [91]. The present study showed that chronic alcohol consumption led to the downregulated expression of butyrate sensors, i.e., GPR109A and SLC5A8 proteins in the rat colon, while the cotreatment of probiotic V and Met prevented these changes in ethanol-fed rats.

As discussed earlier, butyrate plays a very important role in maintaining intestinal permeability, but the absorption of SCFAs is highly enhanced by SLC5A8, and SCFAs are shown to activate signaling pathways via GPR109A. Considering the role of GPR109A as the butyrate receptor and SLC5A8 as the butyrate transporter, we explored the role of Met and butyrate in interacting with GPR109A and SLC5A8 by *in silico* analysis. As expected, being the ligand for both proteins, butyrate showed a good binding affinity with GPR109A and SLC5A8. The main aim of our study was to see if butyrate and Met could work in synergism or enhance the affinity of butyrate towards its receptor. Therefore, we docked both Met and butyrate simultaneously, and we found that the cotreatment of both the ligands enhanced the binding affinities (GPR109A: -9.7 kcal/mol; SLC5A8: -8.3 kcal/mol) as compared to their individual binding affinities (GPR109A: -4.9 and -3.4 kcal/mol; SLC5A8: -5.1 and -4.7 kcal/mol) suggesting their synergism in activating GPR109A and SLC5A8. The *in silico* results are in agreement with the *in vitro* and *in vivo* results where the combination of Met and probiotic V induced the expression of GPR109A and SLC5A8.

## 5. Conclusion

The current study stipulated the confirmation for the potential role of oxidative stress and inflammatory response in ethanol-induced disruption of colonic TJs, intestinal hyperpermeability, and endotoxemia both *in vitro* and *in vivo* and that the supplementation of probiotic V and Met prevents alcoholic-induced gut integrity and permeability, endotoxemia, lipogenesis, inflammatory responses, and ROS generation and upregulates the antioxidant gene expression (Figure 20). We further verify that supplementation of probiotic V and Met effectively prevents ethanol-induced intestinal barrier dysfunction by acting on butyrate receptors and transporters. For the very first time, we report here the combined protective function of probiotic V and Met in the human intestinal epithelial barrier. In addition, also for the first time, the current study showed how the probiotic V and Met could act in synergism by demonstrating the *in silico* interactions of both ligands in inducing the expressions of antioxidant machinery like HO-1 and Nrf-2 and also the butyrate receptor GPR109A and transporter SLC5A8, which matched with our findings, further validating our hypothesis. Such knowledge will provide support for developing the combination of probiotic V and Met as a therapeutic candidate to improve ethanol-induced intestinal epithelial barrier dysfunction or gut leakiness. Additionally, this may provide a strong piece of evidence for further prospective research which will unravel its potential application in humans.

## Data Availability

The authors confirm that the data supporting the findings of this study are available within the article.

## Ethical Approval

The study was conducted according to the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment, Forest and Climate Change, Government of India (New Delhi, India), and approved by the Institutional Animal Ethics Committee (IAEC) of Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (Anand, India) (940/PO/Re/S/06/CPCSEA).

## Conflicts of Interest

The authors declare no conflict of interest.

## Authors' Contributions

Farhin Patel and Kirti Parwani contributed equally to this work.

## Acknowledgments

The authors are thankful to the DST-INSPIRE Fellowship Scheme for providing fellowship and to Charotar University of Science and Technology for the facilities used to carry out the experiments. The authors acknowledge Tapan Patel,

Assistant Professor at P.D. Patel Institute of Applied Sciences, Charotar University of Science and Technology for his help in the histological analysis.

## Supplementary Materials

Supplementary Material: multiple sequence alignment (MSA) and the Ramachandran plot of Nrf-2, GPR109A, and SLC5A8. Supplementary Figure 1: multiple sequence alignment (MSA) was performed between target protein nuclear factor erythroid 2-related factor (NRF-2) of *Rattus norvegicus* (accession no. O54968) and the template protein Kelch-like ECH-associated protein 1 of *Mus musculus* (mouse) (accession no. Q9Z2X8). Due to the unavailability of the target protein in PDB, the modeled protein for the same was built using the structure of the template protein. MSA was performed to establish a sense of conservedness among both proteins and to justify the selection of templates per se. Observed identity is 75.9% and similarity is 24.6% among both the sequences. Supplementary Figure 2: the Nrf-2 Ramachandran plot results were performed using SAVES server v6.0 PROCHECK. Supplementary Figure 3: GPR109A—multiple sequence alignment (MSA) was performed between target protein hydroxycarboxylic acid receptor 2 of *Rattus norvegicus* (accession no. Q80Z39) and the template protein G-protein-coupled receptor APJ (apelin receptor) of *Homo sapiens* (accession no. P35414). Due to the unavailability of the target protein in PDB, the modeled protein for the same was built using the structure of the template protein. MSA was performed to establish a sense of conservedness among both proteins and to justify the selection of templates per se. Observed identity is 97.8% and similarity is 21.8% among both the sequences. Supplementary Figure 4: the GPR109A Ramachandran plot results were performed using MolProbity. Supplementary Figure 5: quality checks on the parameters for the GPR109A modeled protein were performed using the SWISS MODEL. Supplementary Figure 6: SLC5A8—multiple sequence alignment (MSA) was performed between target protein electrogenic sodium monocarboxylate cotransporter of *Rattus norvegicus* (accession no. D3Z9E5) and the template protein putative sodium:solute symporter of *Proteus mirabilis* (accession no. B4EZY7). Due to the unavailability of the target protein in PDB, the modeled protein for the same was built using the structure of the template protein. MSA was performed to establish a sense of conservedness among both proteins and to justify the selection of templates per se. Observed identity is 75.9% and similarity is 24.6% among both the sequences. Supplementary Figure 7: the SLC5A8 protein Ramachandran plot results were performed using MolProbity. Supplementary Figure 8: quality check parameters for the SLC5A8 modeled protein were performed using the SWISS MODEL. (Supplementary Materials)

## References

- [1] R. E. Mann, R. G. Smart, and R. Govoni, "The epidemiology of alcoholic liver disease," *Alcohol Research & Health*, vol. 27, no. 3, pp. 209–219, 2003.



- [2] A. Keshavarzian, E. W. Holmes, M. Patel, F. Iber, J. Z. Fields, and S. Pethkar, "Leaky gut in alcoholic cirrhosis: a possible mechanism for Alcohol-Induced liver damage," *American Journal of Gastroenterology*, vol. 94, no. 1, pp. 200–207, 1999.
- [3] R. K. Rao, A. Seth, and P. Sheth, "Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 286, no. 6, pp. G881–G884, 2004.
- [4] T. Suzuki, "Regulation of intestinal epithelial permeability by tight junctions," *Cellular and molecular life sciences*, vol. 70, no. 4, pp. 631–659, 2013.
- [5] W. Zhong, C. J. McClain, M. Cave, Y. J. Kang, and Z. Zhou, "The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 298, no. 5, pp. G625–G633, 2010.
- [6] W. Y. Chen, M. Wang, J. Zhang, S. S. Barve, C. J. McClain, and S. Joshi-Barve, "Acrolein Disrupts Tight Junction Proteins and Causes Endoplasmic Reticulum Stress-Mediated Epithelial Cell Death Leading to Intestinal Barrier Dysfunction and Permeability," *American Journal of Pathology*, vol. 187, no. 12, pp. 2686–2697, 2017.
- [7] V. Purohit, J. C. Bode, C. Bode et al., "Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium," *Alcohol*, vol. 42, no. 5, pp. 349–361, 2008.
- [8] E. Mutlu, A. Keshavarzian, P. Engen, C. B. Forsyth, M. Sikaroodi, and P. Gillevet, "Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats," *Alcoholism: Clinical and Experimental Research*, vol. 33, no. 10, pp. 1836–1846, 2009.
- [9] P. Mandal, M. T. Pritchard, and L. E. Nagy, "Anti-inflammatory pathways and alcoholic liver disease: role of an adiponectin/interleukin-10/heme oxygenase-1 pathway," *World journal of gastroenterology: WJG*, vol. 16, no. 11, pp. 1330–1336, 2010.
- [10] A. Keshavarzian, S. Choudhary, E. W. Holmes et al., "Preventing gut leakiness by oats supplementation ameliorates alcohol-induced liver damage in rats," *Journal of Pharmacology and Experimental Therapeutics*, vol. 299, no. 2, pp. 442–448, 2001.
- [11] A. Banan, J. Z. Fields, H. Decker, Y. Zhang, and A. Keshavarzian, "Nitric oxide and its metabolites mediate ethanol-induced microtubule disruption and intestinal barrier dysfunction," *Journal of Pharmacology and Experimental Therapeutics*, vol. 294, no. 3, pp. 997–1008, 2000.
- [12] C. B. Forsyth, R. M. Voigt, M. Shaikh et al., "Role for intestinal CYP2E1 in alcohol-induced circadian gene-mediated intestinal hyperpermeability," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 305, no. 2, pp. G185–G195, 2013.
- [13] E. E. Elamin, A. A. Masclee, J. Dekker, and D. M. Jonkers, "Ethanol metabolism and its effects on the intestinal epithelial barrier," *Nutrition reviews*, vol. 71, no. 7, pp. 483–499, 2013.
- [14] A. Banan, A. Keshavarzian, L. Zhang et al., "NF- $\kappa$ B activation as a key mechanism in ethanol-induced disruption of the F-actin cytoskeleton and monolayer barrier integrity in intestinal epithelium," *Alcohol*, vol. 41, no. 6, pp. 447–460, 2007.
- [15] J. K. Nicholson, E. Holmes, J. Kinross et al., "Host-gut microbiota metabolic interactions," *Science*, vol. 336, no. 6086, pp. 1262–1267, 2012.
- [16] S. Leclercq, P. Stärkel, N. M. Delzenne, and P. de Timary, "The gut microbiota: a new target in the management of alcohol dependence?," *Alcohol*, vol. 74, pp. 105–111, 2019.
- [17] R. B. Canani, M. Di Costanzo, L. Leone, M. Pedata, R. Meli, and A. Calignano, "Potential beneficial effects of butyrate in intestinal and extraintestinal diseases," *World Journal of Gastroenterology*, vol. 17, no. 12, 2011.
- [18] G. Xie, W. Zhong, X. Zheng et al., "Chronic ethanol consumption alters mammalian gastrointestinal content metabolites," *Journal of Proteome Research*, vol. 12, pp. 3297–3306, 2013.
- [19] H. Tsuda and T. Miyamoto, "Guidelines for the evaluation of probiotics in food. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food, 2002," *Food Science and Technology Research*, vol. 16, no. 1, pp. 87–92, 2010.
- [20] P. K. Shukla, A. S. Meena, B. Manda et al., "*Lactobacillus plantarum* prevents and mitigates alcohol-induced disruption of colonic epithelial tight junctions, endotoxemia, and liver damage by an EGF receptor-dependent mechanism," *The FASEB Journal*, vol. 32, no. 11, pp. 6274–6292, 2018.
- [21] C. B. Forsyth, A. Farhadi, S. M. Jakate, Y. Tang, M. Shaikh, and A. Keshavarzian, "*Lactobacillus* GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis," *Alcohol*, vol. 43, no. 2, pp. 163–172, 2009.
- [22] I. Bergheim, L. Guo, M. A. Davis et al., "Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1," *Gastroenterology*, vol. 130, no. 7, pp. 2099–2112, 2006.
- [23] MetaHIT consortium, K. Forslund, F. Hildebrand et al., "Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota," *Nature*, vol. 528, no. 7581, pp. 262–266, 2015.
- [24] J. Deng, L. Zeng, X. Lai et al., "Metformin protects against intestinal barrier dysfunction via AMPK $\alpha$ 1-dependent inhibition of JNK signalling activation," *Journal of Cellular and Molecular Medicine*, vol. 22, no. 1, pp. 546–557, 2018.
- [25] W. Wu, S. Wang, Q. Liu, T. Shan, and Y. Wang, "Metformin protects against LPS-induced intestinal barrier dysfunction by activating AMPK pathway," *Molecular Pharmaceutics*, vol. 15, no. 8, pp. 3272–3284, 2018.
- [26] F. Patel, K. Parwani, D. Patel, and P. Mandal, "Metformin and probiotics interplay in amelioration of ethanol-induced oxidative stress and inflammatory response in an in vitro and in vivo model of hepatic injury," *Mediators of Inflammation*, vol. 2021, Article ID 6636152, 31 pages, 2021.
- [27] S. Y. Che, J. W. Yuan, L. Zhang, Z. Ruan, X. M. Sun, and H. Lu, "Puerarin prevents epithelial tight junction dysfunction induced by ethanol in Caco-2 cell model," *Journal of Functional Foods*, vol. 73, article 104079, 2020.
- [28] H. Zhao, C. Zhao, Y. Dong et al., "Inhibition of miR122a by *Lactobacillus rhamnosus* GG culture supernatant increases intestinal occludin expression and protects mice from alcoholic liver disease," *Toxicology letters*, vol. 234, no. 3, pp. 194–200, 2015.
- [29] M. Tanaka-Okamoto, K. Hori, H. Ishizaki et al., "Involvement of afadin in barrier function and homeostasis of mouse intestinal epithelia," *Journal of cell science*, vol. 124, no. 13, pp. 2231–2240, 2011.



- [30] P. P. Bradley, D. A. Priebat, R. D. Christensen, and G. Rothstein, "Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker," *Journal of Investigative Dermatology*, vol. 78, no. 3, pp. 206–209, 1982.
- [31] R. Heidari, V. Taheri, H. R. Rahimi, B. S. Yeganeh, H. Niknahad, and A. Najibi, "Sulfasalazine-induced renal injury in rats and the protective role of thiol-reductants," *Renal Failure*, vol. 38, no. 1, pp. 137–141, 2016.
- [32] M. Uchiyama and M. Mihars, "Determination of malondialdehyde precursor in tissues by thiobarbituric acid," *Analytical Biochemistry*, vol. 86, pp. 271–278, 1978.
- [33] N. Tukozkan, H. Erdamar, and I. Seven, "Measurement of total malondialdehyde in plasma and tissues by high-performance liquid chromatography and thiobarbituric acid assay," *Firat Tip Dergisi*, vol. 11, no. 2, pp. 88–92, 2006.
- [34] L. Zhe-feng, Y. R. An, W.-M. Chen, Q. Z. Wei, and E.-H. Xu, "HPLC method is used to measure the method for butyric acid and sodium butyrate (CN103728389B)," 2016, <https://patents.google.com/patent/CN103728389A/en>.
- [35] K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C_T}$  method," *Methods*, vol. 25, no. 4, pp. 402–408, 2001.
- [36] S. K. Burley, H. M. Berman, C. Bhikadiya et al., "RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy," *Nucleic Acids Research*, vol. 47, no. D1, pp. D464–D474, 2019.
- [37] A. Waterhouse, M. Bertoni, S. Bienert et al., "SWISS-MODEL: homology modelling of protein structures and complexes," *Nucleic Acids Research*, vol. 46, no. W1, pp. W296–W303, 2018.
- [38] A. Bateman, M. J. Martin, S. Orchard et al., "UniProt: the universal protein knowledgebase in 2021," *Nucleic Acids Research*, vol. 49, no. D1, pp. D480–D489, 2021.
- [39] P. Benkert, M. Biasini, and T. Schwede, "Toward the estimation of the absolute quality of individual protein structure models," *Bioinformatics*, vol. 27, no. 3, pp. 343–350, 2011.
- [40] C. J. Williams, J. J. Headd, N. W. Moriarty et al., "MolProbity: more and better reference data for improved all-atom structure validation," *Protein Science*, vol. 27, no. 1, pp. 293–315, 2018.
- [41] J. D. Thompson, D. G. Higgins, and T. J. Gibson, "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," *Nucleic Acids Research*, vol. 22, no. 22, pp. 4673–4680, 1994.
- [42] D. E. Kim, D. Chivian, and D. Baker, "Protein structure prediction and analysis using the Robetta server," *Nucleic acids research*, vol. 32, no. Web Server, Supplement 2, pp. W526–W531, 2004.
- [43] R. A. Laskowski, M. W. MacArthur, D. S. Moss, and J. M. Thornton, "PROCHECK: a program to check the stereochemical quality of protein structures," *Journal of Applied Crystallography*, vol. 26, no. 2, pp. 283–291, 1993.
- [44] A. Shukla, P. Parmar, P. Rao, D. Goswami, and M. Saraf, "Twin peaks: presenting the antagonistic molecular interplay of curcumin with LasR and LuxR quorum sensing pathways," *Current Microbiology*, vol. 77, no. 8, pp. 1800–1810, 2020.
- [45] D. T. Moustakas, P. T. Lang, S. Pegg et al., "Development and validation of a modular, extensible docking program: DOCK 5," *Journal of Computer-Aided Molecular Design*, vol. 20, no. 10–11, pp. 601–619, 2006.
- [46] J. Wang, W. Wang, P. A. Kollman, and D. A. Case, "Automatic atom type and bond type perception in molecular mechanical calculations," *Journal of Molecular Graphics and Modelling*, vol. 25, no. 2, pp. 247–260, 2006.
- [47] E. F. Pettersen, T. D. Goddard, C. C. Huang et al., "UCSF Chimera?A visualization system for exploratory research and analysis," *Journal of Computational Chemistry*, vol. 25, no. 13, pp. 1605–1612, 2004.
- [48] S. Kim, J. Chen, T. Cheng et al., "PubChem in 2021: new data content and improved web interfaces," *Nucleic Acids Research*, vol. 49, no. D1, pp. D1388–D1395, 2019.
- [49] J. Gasteiger and C. Jochum, "An algorithm for the perception of synthetically important rings," *Journal of Chemical Information and Computer Sciences*, vol. 19, no. 1, pp. 43–48, 1979.
- [50] P. Rao, A. Shukla, P. Parmar et al., "Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CLpro of novel coronavirus SARS-CoV-2 identified using docking and molecular dynamics," *Journal of Biomolecular Structure and Dynamics*, pp. 1–13, 2020.
- [51] P. Parmar, A. Shukla, P. Rao, M. Saraf, B. Patel, and D. Goswami, "The rise of gingerol as anti-QS molecule: darkest episode in the LuxR-mediated bioluminescence saga," *Bioorganic Chemistry*, vol. 99, 2020.
- [52] O. Trott and A. J. Olson, "AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading," *Journal of Computational Chemistry*, vol. 31, no. 2, pp. 455–461, 2010.
- [53] BIOVIA, Dassault Systèmes, Dassault Systèmes, Discovery Studio, v17.2 San Diego, 2017.
- [54] E. A. Mutlu, P. M. Gillevet, H. Rangwala et al., "Colonic microbiome is altered in alcoholism," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 302, no. 9, pp. G966–G978, 2012.
- [55] S. Singh, N. A. Osna, and K. K. Kharbanda, "Treatment options for alcoholic and non-alcoholic fatty liver disease: a review," *World Journal of Gastroenterology*, vol. 23, no. 36, pp. 6549–6570, 2017.
- [56] C. Bode and J. C. Bode, "Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol?," *Alcoholism: Clinical & Experimental Research*, vol. 29, pp. 166S–171S, 2005.
- [57] C. Schäfer, A. Parlesak, C. Schütt, J. Christian Bode, and C. Bode, "Concentrations of lipopolysaccharide-binding protein, bactericidal/permeability-increasing protein, soluble CD14 and plasma lipids in relation to endotoxaemia in patients with alcoholic liver disease," *Alcohol and Alcoholism*, vol. 37, no. 1, pp. 81–86, 2002.
- [58] Y. Wang, J. Tong, B. Chang, B. Wang, D. Zhang, and B. Wang, "Effects of alcohol on intestinal epithelial barrier permeability and expression of tight junction-associated proteins," *Molecular Medicine Reports*, vol. 9, no. 6, pp. 2352–2356, 2014.
- [59] K. K. Chaudhry, P. K. Shukla, H. Mir et al., "Glutamine supplementation attenuates ethanol-induced disruption of apical junctional complexes in colonic epithelium and ameliorates gut barrier dysfunction and fatty liver in mice," *The Journal of nutritional biochemistry*, vol. 27, pp. 16–26, 2016.
- [60] B. Chang, L. Sang, Y. wang, J. Tong, D. Zhang, and B. Wang, "The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury," *BMC gastroenterology*, vol. 13, no. 1, 2013.

- [61] R. K. Rao, "Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer," in *Alcohol*, vol. 447 of *Methods in molecular biology*, pp. 171–183, Springer, 2008.
- [62] K. J. Atkinson and R. K. Rao, "Role of protein tyrosine phosphorylation in acetaldehyde-induced disruption of epithelial tight junctions," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 280, no. 6, pp. G1280–G1288, 2001.
- [63] A. S. Meena, P. K. Shukla, P. Sheth, and R. Rao, "EGF receptor plays a role in the mechanism of glutamine-mediated prevention of alcohol-induced gut barrier dysfunction and liver injury," *The Journal of nutritional biochemistry*, vol. 64, pp. 128–143, 2019.
- [64] G. Feldman, J. Mullin, and M. Ryan, "Occludin: Structure, function and regulation," *Advanced Drug Delivery Reviews*, vol. 57, no. 6, pp. 883–917, 2005.
- [65] C. Chelakkot, J. Ghim, and S. H. Ryu, "Mechanisms regulating intestinal barrier integrity and its pathological implications," *Experimental & molecular medicine*, vol. 50, no. 8, pp. 1–9, 2018.
- [66] D. A. Bellos, D. Sharma, M. R. McMullen et al., "Specifically sized hyaluronan (35 kDa) prevents ethanol-induced disruption of epithelial tight junctions through a layilin-dependent mechanism in Caco-2 cells," *Alcoholism: Clinical and Experimental Research*, vol. 43, no. 9, pp. 1848–1858, 2019.
- [67] C. Grander, T. E. Adolph, V. Wieser et al., "Recovery of ethanol-induced Akkermansia muciniphiladepletion ameliorates alcoholic liver disease," *Gut*, vol. 67, no. 5, pp. 891–901, 2018.
- [68] J. Dolpady, C. Sorini, C. Di Pietro et al., "Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment," *Journal of diabetes research*, vol. 2016, Article ID 7569431, 12 pages, 2016.
- [69] J. Wang, H. Ji, S. Wang et al., "Probiotic *Lactobacillus plantarum* promotes intestinal barrier function by strengthening the epithelium and modulating gut microbiota," *Frontiers in microbiology*, vol. 9, p. 1953, 2018.
- [70] L. Chen, J. Wang, Q. You et al., "Activating AMPK to restore tight junction assembly in intestinal epithelium and to attenuate experimental colitis by metformin," *Frontiers in pharmacology*, vol. 9, p. 761, 2018.
- [71] H. Y. Zhou, H. Zhu, X. M. Yao et al., "Metformin regulates tight junction of intestinal epithelial cells via MLCK-MLC signaling pathway," *European Review for Medical and Pharmacological Sciences*, vol. 21, no. 22, pp. 5239–5246, 2017.
- [72] A. I. Cederbaum, "Role of CYP2E1 in ethanol-induced oxidant stress, fatty liver and hepatotoxicity," *Digestive Diseases*, vol. 28, no. 6, pp. 802–811, 2010.
- [73] A. Banan, S. Choudhary, Y. Zhang, J. Z. Fields, and A. Keshavarzian, "Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms," *Journal of Pharmacology and Experimental Therapeutics*, vol. 291, no. 3, pp. 1075–1085, 1999.
- [74] S. Al Kattar, R. Jurjus, A. Pinon et al., "Metformin and probiotics in the crosstalk between colitis-associated colorectal cancer and diabetes in mice," *Cancers*, vol. 12, no. 7, p. 1857, 2020.
- [75] W. G. Kim, H. I. Kim, E. K. Kwon, M. J. Han, and D. H. Kim, "*Lactobacillus plantarum* LC27 and *Bifidobacterium longum* LC67 mitigate alcoholic steatosis in mice by inhibiting LPS-mediated NF- $\kappa$ B activation through restoration of the disturbed gut microbiota," *Food & function*, vol. 9, no. 8, pp. 4255–4265, 2018.
- [76] A. Pandey, S. Verma, and V. L. Kumar, "Metformin maintains mucosal integrity in experimental model of colitis by inhibiting oxidative stress and pro-inflammatory signaling," *Biomedicine & Pharmacotherapy*, vol. 94, pp. 1121–1128, 2017.
- [77] P. Gong and A. I. Cederbaum, "Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1," *Hepatology*, vol. 43, no. 1, pp. 144–153, 2006.
- [78] B. M. Hybertson, B. Gao, S. K. Bose, and J. M. McCord, "Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation," *Molecular aspects of medicine*, vol. 32, no. 4–6, pp. 234–246, 2011.
- [79] S. Del Carmen, A. D. de Moreno de LeBlanc, R. Levit et al., "Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model," *International Immunopharmacology*, vol. 42, pp. 122–129, 2017.
- [80] M. Trevisan, J. Liu, P. Muti, G. Misciagna, A. Menotti, and F. Fucci, "Markers of insulin resistance and colorectal cancer mortality," *Cancer Epidemiology and Prevention Biomarkers*, vol. 10, no. 9, pp. 937–941, 2001.
- [81] M. Tabuchi, J. Kitayama, and H. Nagawa, "Hyperglycemia and hypertriglyceridemia may associate with the adenoma–carcinoma transition in colorectal epithelial cells," *Journal of gastroenterology and hepatology*, vol. 23, no. 6, pp. 985–987, 2008.
- [82] J. J. Galligan, R. L. Smathers, C. T. Shearn et al., "Oxidative stress and the ER stress response in a murine model for early-stage alcoholic liver disease," *Journal of toxicology*, vol. 2012, article 207594, 12 pages, 2012.
- [83] Y. Liu, Q. Ye, Y.-L. Liu, J. Kang, Y. Chen, and W. G. Dong, "*Schistosoma japonicum* attenuates dextran sodium sulfate-induced colitis in mice via reduction of endoplasmic reticulum stress," *World Journal of Gastroenterology*, vol. 23, no. 31, pp. 5700–5712, 2017.
- [84] C. Cernigliaro, A. D'Anneo, D. Carlisi et al., "Ethanol-mediated stress promotes autophagic survival and aggressiveness of colon cancer cells via activation of Nrf2/HO-1 pathway," *Cancers*, vol. 11, no. 4, p. 505, 2019.
- [85] M. L. Hermiston and J. I. Gordon, "Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin," *Science*, vol. 270, no. 5239, pp. 1203–1207, 1995.
- [86] H. Yadav, J. H. Lee, J. Lloyd, P. Walter, and S. G. Rane, "Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion," *Journal of biological chemistry*, vol. 288, no. 35, pp. 25088–25097, 2013.
- [87] M. Thangaraju, G. A. Cresci, K. Liu et al., "GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon," *Cancer research*, vol. 69, no. 7, pp. 2826–2832, 2009.
- [88] S. Sivaprakasam, P. K. Ganapathy, M. O. Sikder et al., "Deficiency of dietary fiber in Slc5a8-null mice promotes bacterial dysbiosis and alters colonic epithelial transcriptome towards proinflammatory milieu," *Canadian Journal of Gastroenterology and Hepatology*, vol. 2019, Article ID 2543082, 12 pages, 2019.
- [89] S. Sivaprakasam, Y. D. Bhutia, S. Yang, and V. Ganapathy, "Short-chain fatty acid transporters: role in colonic

- homeostasis,” *Comprehensive Physiology*, vol. 8, no. 1, pp. 299–314, 2017.
- [90] A. Borthakur, S. Priyamvada, A. Kumar et al., “A novel nutrient sensing mechanism underlies substrate-induced regulation of monocarboxylate transporter-1,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 303, no. 10, pp. G1126–G1133, 2012.
- [91] D. Parada Venegas, M. K. de la Fuente, G. Landskron et al., “Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases,” *Frontiers in immunology*, vol. 10, p. 277, 2019.